| Year |
Citation |
Score |
| 2023 |
Pourebrahim R, Heinz Montoya R, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death & Disease. 14: 371. PMID 37353528 DOI: 10.1038/s41419-023-05844-7 |
0.327 |
|
| 2023 |
Carter BZ, Mak PY, Muftuoglu M, Tao W, Baozhen K, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isqandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczyemba M, Stephan C, ... ... Andreeff M, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. PMID 37339579 DOI: 10.1182/blood.2022019047 |
0.327 |
|
| 2023 |
Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage. Research Square. PMID 36909480 DOI: 10.21203/rs.3.rs-2544760/v1 |
0.325 |
|
| 2022 |
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, ... ... Andreeff M, et al. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine. PMID 35241842 DOI: 10.1038/s41591-022-01696-4 |
0.314 |
|
| 2021 |
Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, et al. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill -ITD acute myeloid leukemia. Haematologica. PMID 34732043 DOI: 10.3324/haematol.2021.278369 |
0.316 |
|
| 2021 |
Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA, ... ... Andreeff M, et al. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. PMID 34127794 DOI: 10.1038/s41375-021-01308-z |
0.312 |
|
| 2021 |
Zeng Z, Ly C, Daver N, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Annals of Hematology. PMID 33787984 DOI: 10.1007/s00277-021-04493-0 |
0.349 |
|
| 2021 |
Lee J, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda MV, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. Blood. PMID 33728465 DOI: 10.1182/blood.2020009081 |
0.31 |
|
| 2020 |
Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. PMID 33353284 DOI: 10.3324/haematol.2020.260331 |
0.356 |
|
| 2020 |
Yuan B, El Dana F, Ly S, Yan Y, Ruvolo V, Shpall EJ, Konopleva M, Andreeff M, Battula VL. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway. Plos One. 15: e0242809. PMID 33253299 DOI: 10.1371/journal.pone.0242809 |
0.343 |
|
| 2020 |
Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, ... ... Andreeff M, et al. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. Journal of Hematology & Oncology. 13: 148. PMID 33148342 DOI: 10.1186/s13045-020-00982-3 |
0.326 |
|
| 2020 |
Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical Mutations. Frontiers in Oncology. 10: 1538. PMID 32984009 DOI: 10.3389/Fonc.2020.01538 |
0.348 |
|
| 2020 |
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, ... ... Andreeff M, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. The Lancet. Haematology. PMID 32896301 DOI: 10.1016/S2352-3026(20)30210-6 |
0.338 |
|
| 2020 |
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, et al. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia & Lymphoma. 1-8. PMID 32755333 DOI: 10.1080/10428194.2020.1802450 |
0.366 |
|
| 2020 |
Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. American Journal of Hematology. PMID 32697348 DOI: 10.1002/Ajh.25943 |
0.401 |
|
| 2020 |
Rytelewski M, Harutyunyan K, Baran N, Mallampati S, Zal MA, Cavazos A, Butler JM, Konoplev S, El Khatib M, Plunkett S, Marszalek JR, Andreeff M, Zal T, Konopleva M. Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model. Frontiers in Oncology. 10: 991. PMID 32695673 DOI: 10.3389/Fonc.2020.00991 |
0.35 |
|
| 2020 |
Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. PMID 32651541 DOI: 10.1038/S41375-020-0949-Z |
0.312 |
|
| 2020 |
Kim BR, Jung SH, Han AR, Park G, Kim HJ, Yuan B, Battula VL, Andreeff M, Konopleva M, Chung YJ, Cho BS. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. Cancers. 12. PMID 32629802 DOI: 10.3390/Cancers12071737 |
0.429 |
|
| 2020 |
Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Post SM, Andreeff M. LGALS1 acts as a pro-survival molecule in AML. Biochimica Et Biophysica Acta. Molecular Cell Research. 118785. PMID 32590026 DOI: 10.1016/J.Bbamcr.2020.118785 |
0.447 |
|
| 2020 |
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, ... ... Andreeff M, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. PMID 32499238 DOI: 10.3324/Haematol.2020.252569 |
0.308 |
|
| 2020 |
Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia. Molecular Cancer Therapeutics. PMID 32404407 DOI: 10.1158/1535-7163.Mct-19-0841 |
0.464 |
|
| 2020 |
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, et al. Clinical value of event-free survival in acute myeloid leukemia. Blood Advances. 4: 1690-1699. PMID 32330243 DOI: 10.1182/Bloodadvances.2019001150 |
0.309 |
|
| 2020 |
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, ... ... Andreeff M, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Advances. 4: 1311-1320. PMID 32251497 DOI: 10.1182/Bloodadvances.2019001267 |
0.327 |
|
| 2020 |
Tabe Y, Konopleva M, Andreeff M. Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML. Frontiers in Oncology. 10: 155. PMID 32133293 DOI: 10.3389/Fonc.2020.00155 |
0.368 |
|
| 2020 |
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Bone marrow niches in haematological malignancies. Nature Reviews. Cancer. PMID 32112045 DOI: 10.1038/S41568-020-0245-2 |
0.412 |
|
| 2020 |
Kadia TM, Garcia-Manero G, Yilmaz M, Dinardo CD, Konopleva M, Montalban-Bravo G, Borthakur G, Jabbour E, Jain N, Andreeff M, Short NJ, Issa GC, Ohanian M, Bose P, Daver NG, et al. Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology. 38: 7539-7539. DOI: 10.1200/Jco.2020.38.15_Suppl.7539 |
0.338 |
|
| 2020 |
Ly S, Nguyen K, Andreeff M, Battula VL. Abstract P3-02-05: Targeting glutamine metabolism inhibits GD2+breast cancer stem cell function in triple negative breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-02-05 |
0.402 |
|
| 2020 |
Zhang W, Chang KH, Basyal M, Jia Y, Ostermann L, Fogler WE, Magnani JL, Andreeff M. Abstract 6038: Combined targeting of E-selectin/CXCR4 and FLT3 by GMI-1359 and sorafenib effectively reduces leukemia cell burden and protects normal hematopoiesis in a patient-derived AML xenograft model Tumor Biology. DOI: 10.1158/1538-7445.Am2020-6038 |
0.368 |
|
| 2020 |
Jaggupilli A, Ly SJ, Borkar R, Nguyen K, Yuan B, Putluri N, Andreeff M, Battula VL. Abstract 3801: Oxidative stress induces glutamine-dependent GD2+ triple negative breast cancer stem cells Cancer Research. 80: 3801-3801. DOI: 10.1158/1538-7445.Am2020-3801 |
0.448 |
|
| 2019 |
Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Advances. 3: 3661-3673. PMID 31751472 DOI: 10.1182/Bloodadvances.2019001068 |
0.412 |
|
| 2019 |
Forte D, Krause DS, Andreeff M, Bonnet D, Méndez-Ferrer S. Updates on the hematological tumor microenvironment and its therapeutic targeting. Haematologica. PMID 31515356 DOI: 10.3324/Haematol.2018.195396 |
0.376 |
|
| 2019 |
Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. PMID 31371419 DOI: 10.3324/Haematol.2019.219261 |
0.458 |
|
| 2019 |
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, ... ... Andreeff M, et al. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology. PMID 31237017 DOI: 10.1002/Ajh.25553 |
0.333 |
|
| 2019 |
Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, ... ... Andreeff M, et al. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. PMID 31127149 DOI: 10.1038/S41375-019-0491-Z |
0.45 |
|
| 2019 |
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, ... ... Andreeff M, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. PMID 31123034 DOI: 10.3324/Haematol.2018.205534 |
0.47 |
|
| 2019 |
Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. Ebiomedicine. PMID 31105032 DOI: 10.1016/J.Ebiom.2019.05.025 |
0.342 |
|
| 2019 |
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, ... ... Andreeff M, et al. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. PMID 31056398 DOI: 10.1016/J.Ccell.2019.03.014 |
0.334 |
|
| 2019 |
Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleava M, Ishizawa J, You MJ, Kantarjian H, ... Andreeff M, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. The Journal of Clinical Investigation. 130. PMID 30829648 DOI: 10.1172/Jci120654 |
0.421 |
|
| 2019 |
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, ... ... Andreeff M, et al. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. PMID 30811597 DOI: 10.1002/Cncr.31986 |
0.333 |
|
| 2019 |
Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Research. PMID 30674535 DOI: 10.1158/0008-5472.CAN-18-0921 |
0.311 |
|
| 2019 |
Daver NG, Zhang W, Graydon R, Dawra V, Xie J, Kumar P, Andreeff M. A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). Journal of Clinical Oncology. 37: TPS7067-TPS7067. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps7067 |
0.335 |
|
| 2019 |
Maiti A, Kantarjian HM, Popat V, Blanco C, Velasquez M, Garcia-Manero G, Konopleva M, Verstovsek S, Andreeff M, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, Dinardo CD, Pierce SA, et al. Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML). Journal of Clinical Oncology. 37: e18513-e18513. DOI: 10.1200/Jco.2019.37.15_Suppl.E18513 |
0.319 |
|
| 2019 |
Chien KS, Benton CB, Class CA, Kadia TM, Dinardo CD, Konopleva M, Andreeff M, Sasaki K, Naqvi K, Ganan Gomez I, Wei Y, Yang H, Pierce SA, Patel KP, Kanagal-Shamanna R, et al. Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. Journal of Clinical Oncology. 37: 7054-7054. DOI: 10.1200/Jco.2019.37.15_Suppl.7054 |
0.319 |
|
| 2019 |
Abbas H, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, et al. IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. Journal of Clinical Oncology. 37: 7041-7041. DOI: 10.1200/Jco.2019.37.15_Suppl.7041 |
0.374 |
|
| 2019 |
Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Andreeff M, Garcia-Manero G, Jabbour E, Daver NG, Borthakur G, Pemmaraju N, Montalban-Bravo G, Benton CB, Short NJ, Bhalla KN, Cortes JE, et al. Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia. Journal of Clinical Oncology. 37: 7034-7034. DOI: 10.1200/Jco.2019.37.15_Suppl.7034 |
0.302 |
|
| 2019 |
Zielinski R, Grela K, Skora S, Jacamo R, Fokt I, Sander M, Remiszewski M, Felix E, Shanmugasundaram M, Zal MA, Andreeff M, Priebe W, Zal T. Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model Blood. 134: 5150-5150. DOI: 10.1182/Blood-2019-131977 |
0.363 |
|
| 2019 |
Muftuoglu M, Ruvolo V, Nishida Y, Mak PY, Ruvolo PP, Carter BZ, Andreeff M. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns Blood. 134: 882-882. DOI: 10.1182/Blood-2019-131784 |
0.318 |
|
| 2019 |
Andreeff M, Zeng J, Soragni A, Ruvolo V, Carter BZ, Ishizawa J, Burks JK, Eisenberg D. Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia Blood. 134: 3786-3786. DOI: 10.1182/Blood-2019-130900 |
0.34 |
|
| 2019 |
Issa GC, Benton CB, Mohanty V, Shen Y, Alaniz Z, Wang F, Futreal PA, Wang W, Jorgensen JL, Navin N, Konopleva MY, Chen K, Andreeff M. Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia Blood. 134: 2717-2717. DOI: 10.1182/Blood-2019-130540 |
0.416 |
|
| 2019 |
Post SM, Ma H, Ruvolo V, Zhang X, Yasuhiro T, Tanaka K, Kozaki R, Yoshizawa T, Cortes JE, DiNardo CD, Konopleva MY, Kornblau SM, Khoury JD, Andreeff M, Ruvolo PP. AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells Blood. 134: 2550-2550. DOI: 10.1182/Blood-2019-128626 |
0.328 |
|
| 2019 |
Pourebrahimabadi R, Alaniz Z, Ostermann LB, Luong HA, Montoya RH, Ruvolo PP, Kornblau SM, Khoury JD, Bueso-Ramos CE, Andreeff M. p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development Blood. 134: 523-523. DOI: 10.1182/Blood-2019-127245 |
0.406 |
|
| 2019 |
Zhao R, Zarabi S, Nii T, Halgas O, Jitkova Y, Ruvolo V, Heese L, Nishida Y, Borthakur GM, Kojima K, Stogniew M, Oster W, Pai E, Davis E, Kantarjian HM, ... ... Andreeff M, et al. Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia Blood. 134: 2562-2562. DOI: 10.1182/Blood-2019-127101 |
0.365 |
|
| 2019 |
Nishida Y, Ishizawa J, Ruvolo V, Kojima K, Montoya RH, Daver NG, Lesegretain A, Shacham S, Andreeff M. Dual Inhibition of MDM2 and XPO1 Synergizes to Induce Apoptosis in Acute Myeloid Leukemia Progenitor Cells with Wild-Type TP53 through Nuclear Accumulation of p53 and Suppression of c-Myc Blood. 134: 2556-2556. DOI: 10.1182/Blood-2019-126950 |
0.368 |
|
| 2019 |
Basyal M, Zhang W, Patel NB, Piya S, Zhang H, Fogler WE, Rice WG, Magnani JL, Borthakur GM, Andreeff M. Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas Blood. 134: 3802-3802. DOI: 10.1182/Blood-2019-126030 |
0.337 |
|
| 2019 |
Carter BZ, Tao W, Mak PY, Zhang Q, Wang X, Kuruvilla VM, Stewart C, Ruvolo V, Battula VL, Konopleva MY, Caenepeel S, Canon J, Hughes P, Morrow P, Andreeff M. Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells Blood. 134: 1267-1267. DOI: 10.1182/Blood-2019-125725 |
0.386 |
|
| 2019 |
Zeng Z, Baran N, Konoplev S, Cavazos A, Zhang Q, Kuruvilla VM, Lorenzi P, Kantarjian HM, Andreeff M, DiNardo CD, Murtie J, Ulanet D, Konopleva MY. Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo Blood. 134: 3911-3911. DOI: 10.1182/Blood-2019-125469 |
0.387 |
|
| 2019 |
Yang H, Tabe Y, Saito K, Yamatani K, Jacamo R, Ma H, Ruvolo V, Zhang Q, Kuruvilla VM, Baran N, Imoto J, Ikeo K, Moriya K, Murakami-Tonami Y, Suzuki K, ... ... Andreeff M, et al. Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML Blood. 134: 911-911. DOI: 10.1182/Blood-2019-125007 |
0.417 |
|
| 2019 |
Carter BZ, Mak PY, Kornblau SM, Tao W, Nishida Y, Ruvolo V, Cidado J, Drew L, Andreeff M. TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1 Blood. 134: 1271-1271. DOI: 10.1182/Blood-2019-124826 |
0.406 |
|
| 2019 |
Han L, Cavazos A, Baran N, Zhang Q, Kuruvilla VM, Feng N, Battula VL, Kantarjian HM, Daver NG, Marszalek JR, Andreeff M, Konopleva MY. Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759 Blood. 134: 5161-5161. DOI: 10.1182/Blood-2019-124475 |
0.308 |
|
| 2019 |
Kim E, Zhang H, Sivina M, Vaca A, Thompson PA, Jain N, Ferrajoli A, Estrov ZE, Keating MJ, Wierda WG, Rice WG, Andreeff M, Burger JA. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells Blood. 134: 3051-3051. DOI: 10.1182/Blood-2019-124473 |
0.336 |
|
| 2019 |
Carter BZ, Mak PY, Warmoes M, Tao W, Lorenzi P, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML Blood. 134: 3727-3727. DOI: 10.1182/Blood-2019-124453 |
0.438 |
|
| 2019 |
Daver NG, Zhang W, Graydon R, Dawra VK, Xie J, Kumar P, Andreeff M. A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) Blood. 134: 1389-1389. DOI: 10.1182/Blood-2019-122585 |
0.355 |
|
| 2019 |
Pawlowsky L, Brauchle B, Pasikhani MK, Wagner AO, Bücklein V, Lichtenegger FS, Kischel R, Metzeler KH, Spiekermann K, Andreeff M, Daver NG, Bergwelt Mv, Subklewe M. Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct Blood. 134: 1265-1265. DOI: 10.1182/Blood-2019-122415 |
0.342 |
|
| 2019 |
DiNardo CD, Olin R, Ishizawa J, Sumi H, Xie J, Kato K, Kumar P, Andreeff M. A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Blood. 134: 3932-3932. DOI: 10.1182/Blood-2019-122241 |
0.355 |
|
| 2019 |
Daver N, Kantarjian H, Mackay S, Flynn B, Basu S, Garcia-Manero G, Alfayez M, Konopleva M, Matthews J, Kornblau S, Jabbour E, Zhou J, Andreeff M. Abstract LB-222: Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-222 |
0.364 |
|
| 2019 |
Morita K, Wang F, Jahn K, Yan Y, Durruthy-Durruthy R, Parikh A, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos C, DiNardo C, ... ... Andreeff M, et al. Abstract 2725: The single-cell atlas of driver mutations in acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2725 |
0.333 |
|
| 2019 |
Yuan B, Ly S, Veletic I, Maldonado K, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Abstract 2040: Acute myeloid leukemia cells induce new bone formation by expanding osteoprogenitor niche in the bone marrow Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2040 |
0.332 |
|
| 2019 |
Ly S, Yuan B, Grimm S, Andreeff M, Bühring H, Battula VL. Abstract 3248: B7-H3, an immune checkpoint protein is overexpressed in AML and the blocking monoclonal antibodies enhance NK cell-mediated apoptosis in AML cells Cancer Research. 79: 3248-3248. DOI: 10.1158/1538-7445.Am2019-3248 |
0.407 |
|
| 2019 |
Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, ... ... Andreeff M, et al. Abstract 2720: Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality Cancer Research. 79: 2720-2720. DOI: 10.1158/1538-7445.Am2019-2720 |
0.397 |
|
| 2019 |
Jappupilli A, Nguyen K, Ly S, Andreeff M, Chelikani P, Battula VL. Abstract 1169: Characterization of a small molecule inhibitor for GD3 synthase (ST8SIA1), a novel target in breast cancer stem-like cells Cancer Research. 79: 1169-1169. DOI: 10.1158/1538-7445.Am2019-1169 |
0.398 |
|
| 2019 |
Strati P, DiNardo C, Daver N, Andreeff M, Konopleva M. Targeting Apoptosis Pathways in Acute Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 19: S53-S54. DOI: 10.1016/J.Clml.2019.07.417 |
0.339 |
|
| 2019 |
Morita K, Wang F, Jahn K, Kuipers J, Yan Y, Matthews J, Little L, Gumbs C, Chen S, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos C, DiNardo C, ... ... Andreeff M, et al. Deconvolution of Clonal Heterogeneity in Acute Myeloid Leukemia using Single-Cell DNA Sequencing Clinical Lymphoma Myeloma and Leukemia. 19: S234. DOI: 10.1016/J.Clml.2019.07.121 |
0.3 |
|
| 2019 |
Nishida Y, Ishizawa J, Ruvolo V, Kojima K, Daver N, Lesegretain A, Shacham S, Andreeff M. Dual Inhibition of MDM2 and XPO1 Induces Synergistic Apoptosis in Wild-type p53 Acute Myeloid Leukemia Through Nuclear Accumulation of p53 and Suppression of c-Myc Clinical Lymphoma Myeloma and Leukemia. 19: S215. DOI: 10.1016/J.Clml.2019.07.085 |
0.336 |
|
| 2019 |
Piya S, Yang Y, Bhattacharya S, Mu H, Ruvolo V, Baran N, Davis RE, Qian Y, You JM, Konopleva M, Kantarjian H, Andreeff M, Borthakur G. Targeting NOTCH1-MYC-CD44 Axis to Eliminate Leukemia Initiating Cells (LIC) in T-ALL Clinical Lymphoma Myeloma and Leukemia. 19: S196-S197. DOI: 10.1016/J.Clml.2019.07.046 |
0.323 |
|
| 2018 |
Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, et al. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. PMID 30530801 DOI: 10.1182/Blood-2018-10-879429 |
0.352 |
|
| 2018 |
Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. PMID 30500073 DOI: 10.1002/Cncr.31896 |
0.381 |
|
| 2018 |
Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Scientific Reports. 8: 16837. PMID 30442990 DOI: 10.1038/S41598-018-35198-6 |
0.427 |
|
| 2018 |
Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, et al. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer Journal. 8: 98. PMID 30341277 DOI: 10.1038/S41408-018-0134-Z |
0.403 |
|
| 2018 |
Le PM, Andreeff M, Battula VL. Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica. PMID 30337364 DOI: 10.3324/Haematol.2018.197004 |
0.407 |
|
| 2018 |
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, et al. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American Journal of Hematology. PMID 30328139 DOI: 10.1002/Ajh.25318 |
0.336 |
|
| 2018 |
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Experimental Hematology & Oncology. 7: 26. PMID 30323983 DOI: 10.1186/S40164-018-0117-6 |
0.329 |
|
| 2018 |
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, ... ... Andreeff M, et al. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in Oncology. 8: 369. PMID 30319961 DOI: 10.3389/Fonc.2018.00369 |
0.343 |
|
| 2018 |
Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun JC, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Molecular Cancer Therapeutics. PMID 30237308 DOI: 10.1158/1535-7163.Mct-18-0399 |
0.37 |
|
| 2018 |
Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, et al. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). American Journal of Hematology. PMID 30028037 DOI: 10.1002/Ajh.25198 |
0.359 |
|
| 2018 |
Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, ... ... Andreeff M, et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nature Communications. 9: 2670. PMID 29991687 DOI: 10.1038/S41467-018-04924-Z |
0.335 |
|
| 2018 |
Griessinger E, Andreeff M. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. Haematologica. 103: 921-923. PMID 29866886 DOI: 10.3324/Haematol.2018.193847 |
0.353 |
|
| 2018 |
Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver N, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica. PMID 29773601 DOI: 10.3324/Haematol.2017.185082 |
0.433 |
|
| 2018 |
Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, et al. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia & Lymphoma. 1-12. PMID 29741984 DOI: 10.1080/10428194.2018.1464158 |
0.373 |
|
| 2018 |
Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochimica Et Biophysica Acta. PMID 29655803 DOI: 10.1016/J.Bbamcr.2018.04.005 |
0.436 |
|
| 2018 |
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, et al. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. The Lancet. Haematology. PMID 29550383 DOI: 10.1016/S2352-3026(18)30021-8 |
0.327 |
|
| 2018 |
Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, ... ... Andreeff M, et al. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica. PMID 29545342 DOI: 10.3324/Haematol.2017.172429 |
0.45 |
|
| 2018 |
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese LE, Ma W, Ma MCJ, DiNardo CD, Pierce SA, Patel KP, Tse A, Davis RE, ... ... Andreeff M, et al. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Research. PMID 29490944 DOI: 10.1158/0008-5472.Can-17-0949 |
0.369 |
|
| 2018 |
Jiang X, Mak PY, Mu H, Mak D, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes JE, Liu Q, ... Andreeff M, et al. Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29463558 DOI: 10.1158/1078-0432.Ccr-17-1556 |
0.347 |
|
| 2018 |
Boddu P, Borthakur G, Naqvi K, Wierda WG, Bose P, Jabbour E, Estrov Z, Burger JA, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Kantarjian HM, Andreeff M, et al. Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML. Journal of Clinical Oncology. 36: 7026-7026. DOI: 10.1200/Jco.2018.36.15_Suppl.7026 |
0.32 |
|
| 2018 |
Benton CB, Al Rawi A, Wang F, Zhang J, Jorgensen JL, Mu H, Schober W, Alaniz Z, Gumbs C, Futreal A, Garcia-Manero G, Kantarjian HM, Navin N, Konopleva MY, Andreeff M. Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing Blood. 132: 2757-2757. DOI: 10.1182/Blood-2018-99-120260 |
0.399 |
|
| 2018 |
Wang X, Mak PY, Ma W, Su X, Mu H, Tao W, Andreeff M, Carter BZ. Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition Blood. 132: 1442-1442. DOI: 10.1182/Blood-2018-99-118367 |
0.301 |
|
| 2018 |
Daver NG, Assi R, Kantarjian HM, Cortes JE, Ravandi F, Konopleva MY, Kadia TM, Borthakur G, Jabbour EJ, DiNardo CD, Velasquez M, Kelly M, Ning J, Nogueras González GM, Pierce SA, ... ... Andreeff M, et al. Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) Blood. 132: 1441-1441. DOI: 10.1182/Blood-2018-99-118028 |
0.32 |
|
| 2018 |
Pourebrahim R, Ruvolo PP, Kornblau SM, Bueso-Ramos CE, Andreeff M. Genetic Dissection of p53 Driven Senescence of Bone Marrow Mesenchymal Cells in Acute Myeloid Leukemia Blood. 132: 2625-2625. DOI: 10.1182/Blood-2018-99-117585 |
0.356 |
|
| 2018 |
Morita K, Wang F, Durruthy-Durruthy R, Parikh A, Matthews J, Little L, Tippen S, Gumbs C, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos CE, DiNardo CD, Ravandi F, ... ... Andreeff M, et al. Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) Blood. 132: 88-88. DOI: 10.1182/Blood-2018-99-117358 |
0.344 |
|
| 2018 |
Yuan B, Ly S, Nguyen K, Tran V, Maldonado K, Kinglsey C, Burks JK, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute Myeloid Leukemia Expands Osteoprogenitor Rich Niche in the Bone Marrow but Resorbs Mature Bone Causing Osteopenia/Osteoporosis in Animal Models Blood. 132: 86-86. DOI: 10.1182/Blood-2018-99-117258 |
0.394 |
|
| 2018 |
Mu H, Ma H, Vaidya A, Bonifant CL, Gottschalk S, Velasquez MP, Andreeff M. IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia Blood. 132: 2724-2724. DOI: 10.1182/Blood-2018-99-116811 |
0.315 |
|
| 2018 |
Zhang W, Yu G, Zhang H, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula VL, Konopleva MY, Rice WG, Andreeff M. Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy Blood. 132: 2635-2635. DOI: 10.1182/Blood-2018-99-116643 |
0.395 |
|
| 2018 |
Daver NG, Pollyea DA, Garcia JS, Jonas BA, Yee KW, Fenaux P, Assouline S, Vey N, Olin R, Roboz GJ, Tafuri A, Visani G, Kirschbrown W, Green C, Ma C, ... ... Andreeff M, et al. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study Blood. 132: 767-767. DOI: 10.1182/Blood-2018-99-116013 |
0.304 |
|
| 2018 |
Piya S, Bhattacharya S, Mu H, Ruvolo V, Baran N, McQueen T, Davis RE, Qian Y, Raina K, You MJ, Konopleva MY, Kantarjian HM, Andreeff M, Borthakur G. Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL Blood. 132: 890-890. DOI: 10.1182/Blood-2018-99-115692 |
0.314 |
|
| 2018 |
Andreeff M, Zhang W, Kumar P, Zernovak O, Daver NG, Isoyama T, Iwanaga K, Togashi N, Seki T. Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models Blood. 132: 2720-2720. DOI: 10.1182/Blood-2018-99-115183 |
0.44 |
|
| 2018 |
Herbrich S, Baggerly K, Alatrash G, Davis RE, Andreeff M, Konopleva MY. CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML Blood. 132: 2768-2768. DOI: 10.1182/Blood-2018-99-114818 |
0.372 |
|
| 2018 |
Bhattacharya S, Piya S, Zhang Q, Baran N, McQueen T, Davis RE, Cosford N, Konopleva MY, Andreeff M, Borthakur G. Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia Blood. 132: 3934-3934. DOI: 10.1182/Blood-2018-99-114817 |
0.344 |
|
| 2018 |
Nishida Y, Ishizawa J, Ruvolo V, Andreeff M. TP73 Isoforms (TAp73 and ΔNp73) Are Overexpressed in Acute Myeloid Leukemias and Potential Therapeutic Targets to Enhance Anti-Leukemia Activities of Bcl-2 and MDM2 Inhibitors Blood. 132: 2629-2629. DOI: 10.1182/Blood-2018-99-113900 |
0.346 |
|
| 2018 |
Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Wang X, Ma H, Mu H, Cidado J, Drew L, Andreeff M. Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions Blood. 132: 768-768. DOI: 10.1182/Blood-2018-99-113491 |
0.475 |
|
| 2018 |
Tabe Y, Yamatani K, Yang H, Saito K, Murakami-Tonami Y, Suzuki K, Zhang W, Kinjo S, Ikeo K, Hosoya M, Mogushi K, Yamaguchi S, Harada H, Miida T, Shah N, ... ... Andreeff M, et al. Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML Blood. 132: 2640-2640. DOI: 10.1182/Blood-2018-99-113195 |
0.448 |
|
| 2018 |
Hoff FW, Ruvolo PP, Qiu Y, Andreeff M, Bont ESd, Horton TM, Kornblau SM. AXL Expression in Pediatric AML Is Associated with Putative LSC and Correlates with a Distinct Set of Proteins Associated with Cell Metabolism, Cell Cycle, and Unfolded Protein Response Blood. 132: 2686-2686. DOI: 10.1182/Blood-2018-99-112555 |
0.316 |
|
| 2018 |
Ruvolo PP, Ma H, Ruvolo V, Zhang X, Mu H, Yasuhiro T, Tanaka K, Yoshizawa T, Zhang W, Cortes JE, Andreeff M, Post SM. TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia Blood. 132: 2642-2642. DOI: 10.1182/Blood-2018-99-112211 |
0.455 |
|
| 2018 |
Han L, Qiu P, Jorgensen JL, Mak D, Burks JK, McQueen T, Zeng Z, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Andreeff M, Guzman ML, Konopleva MY. Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse Blood. 132: 912-912. DOI: 10.1182/Blood-2018-99-111970 |
0.383 |
|
| 2018 |
Yamatani K, Tabe Y, Saito K, Yang H, Murakami-Tonami Y, Suzuki K, Zhang W, Kinjo S, Ikeo K, Mogushi K, Hosoya M, Yamaguchi S, Harada H, Miida T, Shah NP, ... ... Andreeff M, et al. Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3-ITD AML with Secondary Acquired Mutations Blood. 132: 3944-3944. DOI: 10.1182/Blood-2018-99-109957 |
0.301 |
|
| 2018 |
Andreeff M, Marini FC, Westin SN, Coleman RL, Thall PF, Aljahdami V, Qazilbash MH, Rezvani K, Timmons M, Heese L, Wang R, Champlin RE, Shpall EJ, Olson A. Abstract 75: A phase I trial of mesenchymal stem cells transfected with a plasmid secreting interferon beta in advanced ovarian cancer Cancer Research. 78: 75-75. DOI: 10.1158/1538-7445.Am2018-75 |
0.383 |
|
| 2018 |
Nii T, Ishizawa J, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Kojima K, Garnett M, McDermott U, Benes C, Charter N, Deacon S, Elemento O, ... ... Andreeff M, et al. Abstract 4957: The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132 Cancer Research. 78: 4957-4957. DOI: 10.1158/1538-7445.Am2018-4957 |
0.47 |
|
| 2018 |
Nguyen K, Yuan B, Yan Y, Do K, Ueno NT, Andreeff M, Battula VL. Abstract 1929: ST8SIA1 is a novel therapeutic target in TNBC: Regulates FAK-PI3K-AKT-mTOR signaling to promote tumor growth and metastasis Cancer Research. 78: 1929-1929. DOI: 10.1158/1538-7445.Am2018-1929 |
0.354 |
|
| 2018 |
Battula VL, Nguyen K, Somanchi A, Mu H, Ueno NT, Lee D, Andreeff M. Abstract 1766: Dinutuximab targets GD2+breast cancer stem cells and inhibits TNBC tumor growth Immunology. DOI: 10.1158/1538-7445.Am2018-1766 |
0.334 |
|
| 2018 |
Olson A, Marini F, Westin S, Coleman R, Thall P, Al Jhadhami V, Qazilbash MH, Rezvani K, Timmons M, Heese L, Wang R, Champlin RE, Shpall EJ, Andreeff M. A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer Biology of Blood and Marrow Transplantation. 24: S473. DOI: 10.1016/J.Bbmt.2017.12.556 |
0.313 |
|
| 2017 |
Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Advances. 1: 1546-1550. PMID 29296796 DOI: 10.1182/Bloodadvances.2017009019 |
0.303 |
|
| 2017 |
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, ... Andreeff M, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances. 1: 1312-1323. PMID 29296774 DOI: 10.1182/Bloodadvances.2017008227 |
0.354 |
|
| 2017 |
Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B. Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget. 8: 102150-102160. PMID 29254232 DOI: 10.18632/Oncotarget.22235 |
0.484 |
|
| 2017 |
Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M, Andreeff M. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 32: 748-760.e6. PMID 29232553 DOI: 10.1016/J.Ccell.2017.11.003 |
0.37 |
|
| 2017 |
Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, ... Andreeff M, et al. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget. 8: 83354-83369. PMID 29137349 DOI: 10.18632/Oncotarget.19042 |
0.415 |
|
| 2017 |
Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury J, Cortes J, Andreeff M, Post SM. Anexelekto /MER Tyrosine Kinase inhibitor ONO-7475 growth arrests and kills FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Mutant Acute Myeloid Leukemia cells by diverse mechanisms. Haematologica. PMID 28912176 DOI: 10.3324/Haematol.2017.168856 |
0.383 |
|
| 2017 |
Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia (New York, N.Y.). 19: 772-780. PMID 28863346 DOI: 10.1016/J.Neo.2017.07.009 |
0.429 |
|
| 2017 |
Zeng Z, Konopleva M, Andreeff M. Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells. Methods in Molecular Biology (Clifton, N.J.). 1633: 75-86. PMID 28735481 DOI: 10.1007/978-1-4939-7142-8_5 |
0.406 |
|
| 2017 |
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, ... Andreeff M, et al. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica. PMID 28729302 DOI: 10.3324/Haematol.2017.168732 |
0.336 |
|
| 2017 |
Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, ... ... Andreeff M, et al. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. Jci Insight. 2. PMID 28679949 DOI: 10.1172/Jci.Insight.90036 |
0.468 |
|
| 2017 |
Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. PMID 28659338 DOI: 10.3324/Haematol.2016.162230 |
0.409 |
|
| 2017 |
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, ... ... Andreeff M, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. PMID 28596283 DOI: 10.3324/Haematol.2016.163436 |
0.41 |
|
| 2017 |
Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2+ cancer stem cells. Oncotarget. PMID 28415808 DOI: 10.18632/Oncotarget.16294 |
0.379 |
|
| 2017 |
Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget. PMID 28388555 DOI: 10.18632/Oncotarget.16602 |
0.4 |
|
| 2017 |
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen M, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, et al. A phase I clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. PMID 28336527 DOI: 10.1182/Blood-2016-11-750158 |
0.394 |
|
| 2017 |
Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, Meng S, Le XF, Andreeff M, Claret FX. Jab1/Csn5-thioredoxin signaling in relapsed acute monocytic leukemia under oxidative stress. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28270496 DOI: 10.1158/1078-0432.Ccr-16-2426 |
0.329 |
|
| 2017 |
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak D, Mu H, Ruvolo V, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, ... Andreeff M, et al. Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular Cancer Therapeutics. PMID 28270436 DOI: 10.1158/1535-7163.Mct-16-0719 |
0.455 |
|
| 2017 |
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, ... ... Andreeff M, et al. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. PMID 28246192 DOI: 10.1182/Blood-2016-11-749903 |
0.396 |
|
| 2017 |
Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. PMID 28233640 DOI: 10.1016/J.Jcyt.2017.02.002 |
0.359 |
|
| 2017 |
Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, ... ... Andreeff M, et al. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports. 7: 43013. PMID 28220839 DOI: 10.1038/Srep43013 |
0.342 |
|
| 2017 |
Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, AlRawi A, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, et al. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer Journal. 7: e527. PMID 28211885 DOI: 10.1038/Bcj.2017.8 |
0.479 |
|
| 2017 |
Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, et al. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia. Blood. PMID 28143883 DOI: 10.1182/Blood-2016-07-726216 |
0.405 |
|
| 2017 |
Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo VR, Ishizawa J, Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, ... ... Andreeff M, et al. Survival of acute monocytic leukemia cells is driven by fatty acid oxidation-mediated activation of AMPK in bone marrow adipocytes. Cancer Research. PMID 28108519 DOI: 10.1158/0008-5472.Can-16-1645 |
0.432 |
|
| 2017 |
Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang S, Zhou J, Alatrash G, Ciurea SO, Rettig M, DiPersio JF, ... ... Andreeff M, et al. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate, in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28096272 DOI: 10.1158/1078-0432.Ccr-16-1904 |
0.375 |
|
| 2017 |
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, et al. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. American Journal of Hematology. PMID 28052408 DOI: 10.1002/Ajh.24632 |
0.327 |
|
| 2017 |
Daver NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreeff M, et al. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. Journal of Clinical Oncology. 35: e18505-e18505. DOI: 10.1200/Jco.2017.35.15_Suppl.E18505 |
0.356 |
|
| 2017 |
Benton CB, Assi R, Wang F, Pierce S, Patel K, Kornblau SM, AlRawi A, Zhang J, Hamilton BK, Takahashi K, Dinardo CD, Futreal A, Garcia-Manero G, Kadia TM, Kantarjian HM, ... Andreeff M, et al. Frequency and type of JAK3 variants in adult patients with leukemia. Journal of Clinical Oncology. 35: e13117-e13117. DOI: 10.1200/Jco.2017.35.15_Suppl.E13117 |
0.303 |
|
| 2017 |
Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. Journal of Clinical Oncology. 35: 7026-7026. DOI: 10.1200/Jco.2017.35.15_Suppl.7026 |
0.345 |
|
| 2017 |
Morita K, Wang F, Patel K, Bueso-Ramos CE, Abou Zahr A, Gumbs C, Zhang J, Song X, Mendoza M, Wu C, Kornblau S, Dinardo CD, Ravandi F, Garcia-Manero G, Jabbour E, ... Andreeff M, et al. Genomic landscape of adult mixed phenotype acute leukemia (MPAL). Journal of Clinical Oncology. 35: 7023-7023. DOI: 10.1200/Jco.2017.35.15_Suppl.7023 |
0.304 |
|
| 2017 |
Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, Dinardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Huang X, et al. Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Journal of Clinical Oncology. 35: 7020-7020. DOI: 10.1200/Jco.2017.35.15_Suppl.7020 |
0.35 |
|
| 2017 |
Chamoun K, Benton CB, AlRawi A, Jacamo R, Williams P, Wang F, Zhang J, Daver NG, Garcia-Manero G, Kantarjian HM, Futreal A, Andreeff M. Immune-related gene expression deficit of leukemia stem cells (LSC) in AML. Journal of Clinical Oncology. 35: 7011-7011. DOI: 10.1200/Jco.2017.35.15_Suppl.7011 |
0.365 |
|
| 2017 |
Takahashi K, Wang F, Patel K, Bueso-Ramos CE, Issa GC, Song X, Zhang J, Tippen S, Little L, Gumbs C, Ravandi F, Kadia TM, Daver NG, Dinardo CD, Konopleva M, ... Andreeff M, et al. Distinct patterns of somatic mutation clearance and association with clinical outcome in patients with AML. Journal of Clinical Oncology. 35: 7005-7005. DOI: 10.1200/Jco.2017.35.15_Suppl.7005 |
0.305 |
|
| 2017 |
Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Kontoyiannis A, Mendt MC, Imahashi N, Kerbauy LN, Lim FLWI, Li L, Muftuoglu M, Banerjee PP, Champlin RE, Ruvolo PP, ... Andreeff M, et al. The TGF-β/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome Blood. 130: 53-53. DOI: 10.1182/Blood.V130.Suppl_1.53.53 |
0.357 |
|
| 2017 |
Yu G, Zhang W, Ly C, Zhang H, Rice W, Andreeff M. CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status Blood. 130: 4629-4629. DOI: 10.1182/Blood.V130.Suppl_1.4629.4629 |
0.429 |
|
| 2017 |
Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, ... ... Andreeff M, et al. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo Blood. 130: 4454-4454. DOI: 10.1182/Blood.V130.Suppl_1.4454.4454 |
0.404 |
|
| 2017 |
Kerbauy LN, Ang S, Liu E, Banerjee PP, Wu Y, Shaim H, Lim FLWI, Basar R, Li L, Muftuoglu M, Daher M, Imahashi N, Mendt MC, Kaplan M, Mukherjee M, ... ... Andreeff M, et al. Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia Blood. 130: 4453-4453. DOI: 10.1182/Blood.V130.Suppl_1.4453.4453 |
0.373 |
|
| 2017 |
Wang X, Mak PY, Mu H, Tao W, Pachter JA, Weaver DT, Xu B, Andreeff M, Carter BZ. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML Blood. 130: 2653-2653. DOI: 10.1182/Blood.V130.Suppl_1.2653.2653 |
0.473 |
|
| 2017 |
Williams P, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Lopez JH, Kornblau S, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, et al. Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity Blood. 130: 185-185. DOI: 10.1182/Blood.V130.Suppl_1.185.185 |
0.334 |
|
| 2017 |
Tao W, Mak PY, Andreeff M, Carter BZ. Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells Blood. 130: 1586-1586. DOI: 10.1182/Blood.V130.Suppl_1.1586.1586 |
0.43 |
|
| 2017 |
Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, et al. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML Blood. 130: 1345-1345. DOI: 10.1182/Blood.V130.Suppl_1.1345.1345 |
0.345 |
|
| 2017 |
Yang H, Tabe Y, Sekihara K, Saito K, Ma H, Ruvolo V, Imoto J, Ikeo K, Mogushi K, Hosoya M, Hayashizaki Y, Yamanaka Y, Miida T, Andreeff M, Marszalek JR, et al. Novel Oxidative Phosphorylation Inhibitor IACS-010759 Induces AMPK-Dependent Apoptosis of AML Cells Blood. 130: 1245-1245. DOI: 10.1182/Blood.V130.Suppl_1.1245.1245 |
0.427 |
|
| 2017 |
Zhou X, Yuan B, Yan Y, Nguyen K, Ruvolo V, Mu H, McQueen T, Shpall EJ, Do K, Konopleva M, Andreeff M, Battula VL. Bone Marrow Stromal Cells Induce ALDH+ Stem Cell Phenotype and Chemotherapy Resistance in AML Cells through TGF-β1 Mediated Signaling: Reversal By TGFβ Inhibitor Galunisertib Blood. 130: 1163-1163. DOI: 10.1182/Blood.V130.Suppl_1.1163.1163 |
0.487 |
|
| 2017 |
Zhang W, Zhang H, Local A, Rice WG, Ly CJ, Yu G, Howell SB, Andreeff M. Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3 Clinical Cancer Research. 23: 25-25. DOI: 10.1158/1557-3265.Hemmal17-25 |
0.363 |
|
| 2017 |
Achreja A, Zhao H, Zhu Z, Gerszberg J, Konopleva MY, Andreeff M, Nagrath D. Abstract 439: Metabolic flux analysis reveals targets to sensitize chemoresistance in acute myeloid leukemia induced by mesenchymal stromal cell-derived exosomes Cancer Research. 77: 439-439. DOI: 10.1158/1538-7445.Am2017-439 |
0.379 |
|
| 2017 |
Zhao H, Achreja A, Zhu Z, Rawi AN, Konopleva M, Andreeff M, Nagrath D. Abstract 4323: Metabolic reprogramming in acute myeloid leukemia cells by mesenchymal stromal cell-derived exosomes induces chemoresistance Cancer Research. 77: 4323-4323. DOI: 10.1158/1538-7445.Am2017-4323 |
0.428 |
|
| 2017 |
Battula VL, Yan Y, Nguyen K, Do K, Andreeff M. Abstract 2898: ST8SIA1 is up-regulated in triple negative breast cancer and its expression is positively correlated withTP53mutations and a cancer stem cell gene signature Cancer Research. 77: 2898-2898. DOI: 10.1158/1538-7445.Am2017-2898 |
0.308 |
|
| 2017 |
Nguyen K, Yan Y, Bartholomeusz C, Ueno N, Do K, Andreeff M, Battula VL. Abstract 2875: Knockout of ST8SIA1 inhibits tumorigenesis in triple negative breast cancer by inducing PTEN and ganglioside GM1 mediated tumor growth arrest Cancer Research. 77: 2875-2875. DOI: 10.1158/1538-7445.Am2017-2875 |
0.435 |
|
| 2017 |
Prabhu VV, Madhukar N, Tarapore R, Garnett M, McDermott U, Benes C, Charter N, Deacon S, Oster W, Andreeff M, Elemento O, Stogniew M, Allen J. Abstract 1155: Potent anti-cancer effects of selective GPR132/G2A agonist imipridone ONC212 in leukemia and lymphoma Cancer Research. 77: 1155-1155. DOI: 10.1158/1538-7445.Am2017-1155 |
0.429 |
|
| 2017 |
Daver N, Garcia-Manero G, Basu S, Cortes J, Ravandi F, Jabbour E, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, et al. Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 17: S9. DOI: 10.1016/J.Clml.2017.09.036 |
0.333 |
|
| 2017 |
Bhattacharya S, Piya S, McQueen T, Konopleva M, Andreeff M, Borthakur G. Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 17: S8-S9. DOI: 10.1016/J.Clml.2017.09.035 |
0.337 |
|
| 2017 |
Zhang Q, Han L, Pan R, Shi C, Jeremy R, John Ma MC, Kurtz S, Mu H, Ruvolo VR, Ma H, Mi Y, Tyner J, Anthony L, Davis RE, Andreeff M, et al. MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models Clinical Lymphoma Myeloma and Leukemia. 17: S2. DOI: 10.1016/J.Clml.2017.09.025 |
0.31 |
|
| 2017 |
Han L, Zhang Q, Shi C, Cavazos A, Ruvolo VR, Leverson JD, Dail M, Phillips DC, Chen J, Jin SS, Jacamo R, Daver N, Jabbour E, Kantarjian HM, Andreeff M, et al. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.064 |
0.325 |
|
| 2017 |
Zhang W, Zhang H, Local A, Rice W, Ly C, Yu G, Howell S, Andreeff M. CG′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3 Clinical Lymphoma Myeloma and Leukemia. 17: S274-S275. DOI: 10.1016/J.Clml.2017.07.051 |
0.329 |
|
| 2017 |
Bhattacharya S, Mu H, Piya S, Zhang W, McQueen T, Paradiso L, Oberkovitz G, Benami E, Andreeff M, Borthakur G. Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 17: S273. DOI: 10.1016/J.Clml.2017.07.049 |
0.381 |
|
| 2016 |
Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, ... ... Andreeff M, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. PMID 28003274 DOI: 10.1182/Blood-2016-09-736686 |
0.312 |
|
| 2016 |
Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy. 1-2. PMID 27797294 DOI: 10.1080/15548627.2016.1245263 |
0.369 |
|
| 2016 |
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, ... Andreeff M, et al. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. American Journal of Hematology. PMID 27673440 DOI: 10.1002/Ajh.24568 |
0.366 |
|
| 2016 |
Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. PMID 27657543 DOI: 10.1002/Cncr.30361 |
0.314 |
|
| 2016 |
Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8: 355ra117. PMID 27605552 DOI: 10.1126/Scitranslmed.Aag1180 |
0.452 |
|
| 2016 |
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, ... ... Andreeff M, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814 |
0.356 |
|
| 2016 |
Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. PMID 27540013 DOI: 10.1182/Blood-2016-04-708750 |
0.403 |
|
| 2016 |
Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biology & Medicine. 13: 248-59. PMID 27458532 DOI: 10.20892/J.Issn.2095-3941.2016.0023 |
0.44 |
|
| 2016 |
Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. PMID 27391151 DOI: 10.18632/Oncotarget.10397 |
0.458 |
|
| 2016 |
Rau RE, Rodriguez B, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y, Sweet S, Chevassut T, Andreeff M, Kornblau SM, Li W, et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. PMID 27335278 DOI: 10.1182/Blood-2015-11-684225 |
0.385 |
|
| 2016 |
Kojima K, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Experimental Hematology. PMID 27327543 DOI: 10.1016/J.Exphem.2016.05.014 |
0.385 |
|
| 2016 |
Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget. PMID 27283492 DOI: 10.18632/Oncotarget.9843 |
0.337 |
|
| 2016 |
Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. PMID 27268264 DOI: 10.1182/Blood-2016-01-692244 |
0.431 |
|
| 2016 |
Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes. Experimental Hematology. PMID 27208809 DOI: 10.1016/J.Exphem.2016.05.003 |
0.313 |
|
| 2016 |
Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, et al. A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia. American Journal of Hematology. PMID 27169385 DOI: 10.1002/Ajh.24415 |
0.352 |
|
| 2016 |
Han X, Medeiros LJ, Zhang YH, You MJ, Andreeff M, Konopleva M, Bueso-Ramos CE. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. PMID 27155969 DOI: 10.1016/J.Clml.2016.03.012 |
0.356 |
|
| 2016 |
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... Andreeff M, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008 |
0.332 |
|
| 2016 |
Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget. PMID 26956049 DOI: 10.18632/oncotarget.7911 |
0.373 |
|
| 2016 |
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, ... ... Andreeff M, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9: ra17. PMID 26884599 DOI: 10.1126/Scisignal.Aac4380 |
0.332 |
|
| 2016 |
Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Research. PMID 26822154 DOI: 10.1158/0008-5472.Can-15-1580 |
0.411 |
|
| 2016 |
Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Eric Davis R, Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochimica Et Biophysica Acta. 1863: 562-71. PMID 26704388 DOI: 10.1016/J.Bbamcr.2015.12.008 |
0.429 |
|
| 2016 |
Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Abruzzo L, Zuo Z, Huh Y, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen MH, Hu P, Medeiros LJ, et al. MYC protein expression as prognostic in acute myeloid leukemia. Journal of Clinical Oncology. 34: 7019-7019. DOI: 10.1200/Jco.2016.34.15_Suppl.7019 |
0.364 |
|
| 2016 |
Ohanian M, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Alvarado Y, Konopleva M, Lim M, Pierce S, O'Brien SM, Tari Ashizawa A, Verstovsek S, Wierda WG, Cortes JE. Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies. Journal of Clinical Oncology. 34: 7010-7010. DOI: 10.1200/Jco.2016.34.15_Suppl.7010 |
0.331 |
|
| 2016 |
Han L, Zhang Q, Shi C, Cavazos A, Ruvolo V, Leverson J, Monique D, Phillips DC, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour EJ, Kantarjian HM, Andreeff M, et al. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models Blood. 128: 97-97. DOI: 10.1182/Blood.V128.22.97.97 |
0.465 |
|
| 2016 |
Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) Blood. 128: 763-763. DOI: 10.1182/Blood.V128.22.763.763 |
0.336 |
|
| 2016 |
Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis ER, Ruvolo V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects Blood. 128: 748-748. DOI: 10.1182/Blood.V128.22.748.748 |
0.467 |
|
| 2016 |
DiNardo CD, Rosenthal J, Andreeff M, Zernovak O, Kumar P, Gajee R, Chen S, Rosen M, Song S, Kochan J, Limsakun T, Olin R. Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results Blood. 128: 593-593. DOI: 10.1182/Blood.V128.22.593.593 |
0.333 |
|
| 2016 |
Jacamo RO, Zhang Q, McQueen T, Davis RE, Konopleva M, Andreeff M. Silencing TG2 in Acute Myeloid Leukemia. Possible Role of TG2 in Microenvironment-Mediated Chemoresistance Blood. 128: 5087-5087. DOI: 10.1182/Blood.V128.22.5087.5087 |
0.474 |
|
| 2016 |
Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Maiti A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, et al. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents Blood. 128: 4328-4328. DOI: 10.1182/Blood.V128.22.4328.4328 |
0.308 |
|
| 2016 |
Gleixner KV, Schneeweiss MA, Herrmann H, Blatt K, Berger D, Eisenwort G, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Gunning PT, Maeda H, Moriggl R, Deininger MW, ... ... Andreeff M, et al. Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml Blood. 128: 4241-4241. DOI: 10.1182/Blood.V128.22.4241.4241 |
0.381 |
|
| 2016 |
Nii T, Ishizawa J, Zhao R, Zeng J, Chachad D, Kojima K, Konopleva M, Davis RE, Allen JE, Stogniew M, Andreeff M. ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies Blood. 128: 4059-4059. DOI: 10.1182/Blood.V128.22.4059.4059 |
0.454 |
|
| 2016 |
Baran N, Molina J, Cavazos A, Harutyunyan K, Feng N, Gay J, Piya S, Shanmuga Velandy S, Jabbour EJ, Andreeff M, Tiziani S, Ferrando AA, Zweidler-McKay P, Di Francesco ME, Marszalek JR, et al. Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models Blood. 128: 4028-4028. DOI: 10.1182/Blood.V128.22.4028.4028 |
0.367 |
|
| 2016 |
Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias Blood. 128: 3997-3997. DOI: 10.1182/Blood.V128.22.3997.3997 |
0.376 |
|
| 2016 |
Tabe Y, Sekihara K, Saitoh K, Ruvolo V, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Novel Fatty Acid Oxidation Inhibitor Avocatinb Induces AMPK-Dependent Apoptosis of AML Cells Co-Cultured with BM-Adipocytes Blood. 128: 3947-3947. DOI: 10.1182/Blood.V128.22.3947.3947 |
0.461 |
|
| 2016 |
Zeng J, Soragni A, Ishizawa J, Ruvolo V, Benton CB, McQueen T, Ruvolo P, Qi Y, Su X, Burks J, Eisenberg DS, Andreeff M. Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML Blood. 128: 3944-3944. DOI: 10.1182/Blood.V128.22.3944.3944 |
0.383 |
|
| 2016 |
Ruvolo P, Ma H, Ruvolo V, Mu H, Schober W, Yasuhiro T, Yoshizawa T, Gallardo M, Zhang X, Khoury JD, Cortes J, Andreeff M, Post SM. AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells Blood. 128: 3939-3939. DOI: 10.1182/Blood.V128.22.3939.3939 |
0.371 |
|
| 2016 |
Zeng Z, Ly C, Mak D, Shah NP, Konopleva M, Andreeff M. AMG925, a Dual FLT3-CDK4/6 Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Progenitor/Stem Cells Blood. 128: 3938-3938. DOI: 10.1182/Blood.V128.22.3938.3938 |
0.458 |
|
| 2016 |
Zhang W, Ly C, Zhang Q, Mu H, Battula VL, Patel N, Schober W, Han X, Fogler WE, Magnani JL, Andreeff M. Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model Blood. 128: 3519-3519. DOI: 10.1182/Blood.V128.22.3519.3519 |
0.473 |
|
| 2016 |
Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau SM, Ohanian M, Alfonso Pierola A, et al. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Blood. 128: 346-346. DOI: 10.1182/Blood.V128.22.346.346 |
0.352 |
|
| 2016 |
Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, et al. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) Blood. 128: 2900-2900. DOI: 10.1182/Blood.V128.22.2900.2900 |
0.377 |
|
| 2016 |
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, DiNardo CD, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b Blood. 128: 2893-2893. DOI: 10.1182/Blood.V128.22.2893.2893 |
0.359 |
|
| 2016 |
Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, ... ... Andreeff M, et al. Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type Blood. 128: 2852-2852. DOI: 10.1182/Blood.V128.22.2852.2852 |
0.333 |
|
| 2016 |
Jiang X, Mak PY, Mu H, Mak D, Zhang Q, Konopleva M, Andreeff M, Carter BZ. Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo Blood. 128: 2828-2828. DOI: 10.1182/Blood.V128.22.2828.2828 |
0.425 |
|
| 2016 |
Chachad D, Ishizawa J, Danter WR, Mills G, Andreeff M, Kojima K. The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism Blood. 128: 2757-2757. DOI: 10.1182/Blood.V128.22.2757.2757 |
0.367 |
|
| 2016 |
Borthakur G, Tallman MS, Ofran Y, Foran JM, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman J, Al-Rawi A, Wang R, Peled A, Abraham M, Pereg Y, ... ... Andreeff M, et al. The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia Blood. 128: 2745-2745. DOI: 10.1182/Blood.V128.22.2745.2745 |
0.459 |
|
| 2016 |
Ly C, Zhang W, Ruvolo V, Shah NP, Andreeff M. Mechanism-Based Combinatorial Strategy for Overcoming FLT3-Inhibitor Resistance in Dual FLT3 ITD and TKD Point Mutations Blood. 128: 2328-2328. DOI: 10.1182/Blood.V128.22.2328.2328 |
0.408 |
|
| 2016 |
Wang X, Mak PY, Mu H, Jiang X, Mak D, Pachter JA, Weaver DT, Xu B, Andreeff M, Carter BZ. Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML Blood. 128: 1574-1574. DOI: 10.1182/Blood.V128.22.1574.1574 |
0.518 |
|
| 2016 |
Tabe Y, Sekihara K, Saitoh K, Monma N, Ikeo K, Kaczkowski B, Zhang W, Yamanaka Y, Miida T, Shah NP, Harada H, Hayashizaki Y, Konopleva M, Andreeff M. Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcriptional Signatures of FLT3-ITD with Secondary D835 TKD Mutations in Acute Myeloid Leukemia Blood. 128: 1530-1530. DOI: 10.1182/Blood.V128.22.1530.1530 |
0.405 |
|
| 2016 |
Zhang Q, Han L, Shi C, Pan R, MA MCJ, Ryan J, Kurtz SE, Mu H, Ruvolo V, Ma H, Andreeff M, Mi Y, Tyner JW, Leverson J, Letai A, et al. Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Blood. 128: 101-101. DOI: 10.1182/Blood.V128.22.101.101 |
0.42 |
|
| 2016 |
Zhang W, Mu H, Zhang Q, Patel NB, Fogler WE, Magnani JL, Andreeff M. Abstract 3284: Targeting E-selectin/CXCR4 with GMI-1359 effectively mobilizes bone marrow leukemia cells and enhances FLT3 inhibitor-induced anti-leukemia efficacy in a murine acute myeloid leukemia model Cancer Research. 76: 3284-3284. DOI: 10.1158/1538-7445.Am2016-3284 |
0.416 |
|
| 2016 |
Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Kornblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Verstovsek S, Ruvolo P, Kadia T, Matthews J, et al. Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) Cancer Research. 76: 3205-3205. DOI: 10.1158/1538-7445.Am2016-3205 |
0.355 |
|
| 2016 |
Dettman E, Doykan C, Ishizawa J, Zhang W, Walker A, Blum W, Klisovic R, Cardone M, Andreeff M, Johnson A. Abstract 2282: Decitabine response in FLT3-negative AML is associated with mitochondrial priming Cancer Research. 76: 2282-2282. DOI: 10.1158/1538-7445.Am2016-2282 |
0.396 |
|
| 2016 |
Sekihara K, Saitoh K, Miida T, Andreeff M, Konopleva M, Tabe Y. The Simultaneous Blockade of mTOR and Nuclear Transporter Exportin-1 Induces Synergistic Antitumor Effect through Pro-Survival Metabolism in Mantle Cell Lymphoma Clinical Lymphoma Myeloma and Leukemia. 16: S117-S118. DOI: 10.1016/J.Clml.2016.07.170 |
0.341 |
|
| 2016 |
Carter B, Zhou H, Mak P, Mu H, Mak D, Zeng Z, Cortes J, Andreeff M. Inhibition of B-Catenin and Bcr-Abl Tyrosine Kinase Synergistically Targets Blast Crisis CML Cells and Stem/Progenitor Cells In Vitro and In Vivo Clinical Lymphoma Myeloma and Leukemia. 16: S63-S64. DOI: 10.1016/J.Clml.2016.07.092 |
0.393 |
|
| 2016 |
Piya S, Lorenzi P, McQueen T, Davis E, Qian Y, Andreeff M, Borthakur G. ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets Clinical Lymphoma Myeloma and Leukemia. 16: S36-S37. DOI: 10.1016/J.Clml.2016.07.051 |
0.355 |
|
| 2016 |
Borthakur G, Tallman M, Ofran Y, Foran J, Uy G, DiPersio J, Nagler A, Rowe J, Showel M, Altman J, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, ... ... Andreeff M, et al. Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients Clinical Lymphoma Myeloma and Leukemia. 16: S28. DOI: 10.1016/J.Clml.2016.07.040 |
0.301 |
|
| 2015 |
Sphyris N, Sarkar TR, Battula VL, Andreeff M, Mani SA. GD2 and GD3 synthase: novel drug targets for cancer therapy. Molecular & Cellular Oncology. 2: e975068. PMID 27308452 DOI: 10.4161/23723556.2014.975068 |
0.393 |
|
| 2015 |
Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. Bba Clinical. 4: 59-68. PMID 26674329 DOI: 10.1016/J.Bbacli.2015.07.001 |
0.335 |
|
| 2015 |
Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, ... ... Andreeff M, et al. Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in pre-clinical leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26603259 DOI: 10.1158/1078-0432.Ccr-14-3378 |
0.301 |
|
| 2015 |
Nishida Y, Maeda A, Chachad D, Ishizawa J, Yi Hua Q, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy. Cancer Science. PMID 26450753 DOI: 10.1111/Cas.12833 |
0.401 |
|
| 2015 |
Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6: 30487-99. PMID 26431162 DOI: 10.18632/Oncotarget.5890 |
0.381 |
|
| 2015 |
Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, ... Andreeff M, et al. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. Plos One. 10: e0137210. PMID 26340096 DOI: 10.1371/journal.pone.0137210 |
0.312 |
|
| 2015 |
Zhang Y, Nowicka A, Solley TN, Wei C, Parikh A, Court L, Burks JK, Andreeff M, Woodward WA, Dadbin A, Kolonin MG, Lu KH, Klopp AH. Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. Plos One. 10: e0136361. PMID 26317219 DOI: 10.1371/Journal.Pone.0136361 |
0.349 |
|
| 2015 |
Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, et al. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology. PMID 26299958 DOI: 10.1002/Ajh.24140 |
0.31 |
|
| 2015 |
Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. PMID 26045609 DOI: 10.1182/Blood-2014-10-604975 |
0.434 |
|
| 2015 |
Cho BS, Zeng Z, Mu H, Wang Z, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 126: 222-32. PMID 26031918 DOI: 10.1182/Blood-2015-02-628677 |
0.446 |
|
| 2015 |
Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, et al. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells (Dayton, Ohio). 33: 2400-15. PMID 25966666 DOI: 10.1002/Stem.2053 |
0.39 |
|
| 2015 |
Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, ... ... Andreeff M, et al. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50: 939-46. PMID 25867648 DOI: 10.1038/Bmt.2015.58 |
0.423 |
|
| 2015 |
Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 125: 2885-92. PMID 25778529 DOI: 10.1182/Blood-2015-01-607366 |
0.354 |
|
| 2015 |
Mallampati S, Leng X, Ma H, Zeng J, Li J, Wang H, Lin K, Lu Y, Yang Y, Sun B, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, et al. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. Blood. 125: 2968-73. PMID 25712988 DOI: 10.1182/Blood-2014-05-576421 |
0.415 |
|
| 2015 |
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, ... ... Andreeff M, et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 100: 927-34. PMID 25682597 DOI: 10.3324/Haematol.2014.118455 |
0.347 |
|
| 2015 |
Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 87: 346-56. PMID 25598437 DOI: 10.1002/Cyto.A.22628 |
0.431 |
|
| 2015 |
Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, ... ... Andreeff M, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 125: 249-60. PMID 25406351 DOI: 10.1182/Blood-2014-04-572255 |
0.378 |
|
| 2015 |
Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene. 34: 2958-67. PMID 25109336 DOI: 10.1038/Onc.2014.245 |
0.374 |
|
| 2015 |
Short NJ, Benton CB, Nogueras-Gonzalez GM, Hokanson J, Gu L, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes JE, Kantarjian HM, Quintas-Cardama A, Andreeff M. Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy. Journal of Clinical Oncology. 33: e18045-e18045. DOI: 10.1200/Jco.2015.33.15_Suppl.E18045 |
0.315 |
|
| 2015 |
Borthakur G, Foran JM, Wang ES, Rakkar A, Minderman H, Burns J, Andreeff M, Tibes R. A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine Blood. 126: 93-93. DOI: 10.1182/Blood.V126.23.93.93 |
0.392 |
|
| 2015 |
Piya S, McQueen T, Mak D, Konopleva M, Zweidler-McKay P, Lu J, Qian Y, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4 Blood. 126: 675-675. DOI: 10.1182/Blood.V126.23.675.675 |
0.448 |
|
| 2015 |
Pan R, Ruvolo V, Mu H, Zheng Z, Leverson J, Kojima K, Konopleva M, Nichols G, Andreeff M. BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms Blood. 126: 673-673. DOI: 10.1182/Blood.V126.23.673.673 |
0.379 |
|
| 2015 |
Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour EJ, Bhalla KN, Konopleva M, Daver N, DiNardo C, Bose P, Patel KP, Pierce S, et al. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia Blood. 126: 564-564. DOI: 10.1182/Blood.V126.23.564.564 |
0.324 |
|
| 2015 |
Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Andreeff M, Konopleva M, Sasai K, Miida T. Low-Dose Ionizing Radiation Modulates Expression of Gpam in Immortalized EBV Infected B Cells through miRNA Network Blood. 126: 4829-4829. DOI: 10.1182/Blood.V126.23.4829.4829 |
0.327 |
|
| 2015 |
Kornblau SM, Ruvolo P, Wang R, Ruvolo V, Qiu Y, Battula VL, Zeng Z, McQueen T, Yoo S, Konopleva M, Andreeff M. Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC Blood. 126: 3813-3813. DOI: 10.1182/Blood.V126.23.3813.3813 |
0.387 |
|
| 2015 |
Zhang W, Patel N, Fogler WE, Magnani JL, Andreeff M. The Dual E-Selectin/CXCR4 Inhibitor, GMI-1359, Enhances Efficacy of Anti-Leukemia Chemotherapy in FLT3-ITD Mutated Acute Myeloid Leukemia Blood. 126: 3790-3790. DOI: 10.1182/Blood.V126.23.3790.3790 |
0.451 |
|
| 2015 |
Ravandi F, Cortes JE, Garcia-Manero G, Estey E, Borthakur G, Jabbour EJ, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, Kornblau SM, Kadia T, Daver N, DiNardo C, ... ... Andreeff M, et al. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin Blood. 126: 3776-3776. DOI: 10.1182/Blood.V126.23.3776.3776 |
0.306 |
|
| 2015 |
Tabe Y, Yamamoto S, Kikkawa M, Taka H, Mogushi K, Mastushita H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Novel FAO Inhibitor Avocatin B Induces Apoptosis of Acute Monocytic Leukemia Cells in Adipocyte Co-Culture System Via ER Stress and ATF4 Activation Blood. 126: 3692-3692. DOI: 10.1182/Blood.V126.23.3692.3692 |
0.416 |
|
| 2015 |
Jiang X, Mak PY, Mu H, Zhang W, Mak D, Ruvolo P, McQueen T, Zhou H, Cortes JE, Andreeff M, Carter BZ. Concurrent Inhibition of Beta-Catenin/CBP and FLT3 Strongly Suppresses c-Myc and Synergistically Induces Apoptosis in FLT3 Mutant AML Cells Blood. 126: 3685-3685. DOI: 10.1182/Blood.V126.23.3685.3685 |
0.429 |
|
| 2015 |
Tabe Y, Konopleva M, Monma N, Ikeo K, Mogushi K, Yamanaka Y, Matsushita H, Miida T, Hayashizaki Y, Andreeff M. Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcript Signatures in Acute Monocytic Leukemia Cells By Fatty Acid Oxidation Inhibition Blood. 126: 3631-3631. DOI: 10.1182/Blood.V126.23.3631.3631 |
0.387 |
|
| 2015 |
Zhang Q, Pan R, Han L, Shi C, Kurtz SE, Mu H, Ma H, Andreeff M, Leverson J, Tyner JW, Mi Y, Konopleva M. Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models Blood. 126: 328-328. DOI: 10.1182/Blood.V126.23.328.328 |
0.378 |
|
| 2015 |
Ravandi F, Jeffrey JL, Jabbour EJ, Borthakur G, Kadia T, Faderl S, Pierce S, Brandt M, Wang SA, Konoplev S, Daver N, Pemmaraju N, Garcia-Manero G, Andreeff M, Konopleva M, et al. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia Blood. 126: 2579-2579. DOI: 10.1182/Blood.V126.23.2579.2579 |
0.315 |
|
| 2015 |
Vélez Luján J, Zacharias N, Rakheja D, Bhagat TD, Lee J, Dutta P, Gonzalez D, Andreeff M, Bhattacharya PK, Verma A, Konopleva M. Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML Blood. 126: 2559-2559. DOI: 10.1182/Blood.V126.23.2559.2559 |
0.422 |
|
| 2015 |
Ishizawa J, Jacamo RO, Kojima K, Chachad D, Ruvolo V, Ruvolo P, Zang W, Tabe Y, Konopleva M, Devine W, Lindquist S, Porco JA, Whitesell L, Andreeff M. Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia By Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach Blood. 126: 2548-2548. DOI: 10.1182/Blood.V126.23.2548.2548 |
0.496 |
|
| 2015 |
Borthakur G, Ofran Y, Nagler A, Rowe JM, Foran JM, Uy GL, DiPersio JF, Altman JK, Frankfurt O, Tallman MS, Peled A, Pereg Y, Vainstein A, Aharon A, AlRawi A, ... ... Andreeff M, et al. The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia Blood. 126: 2546-2546. DOI: 10.1182/Blood.V126.23.2546.2546 |
0.425 |
|
| 2015 |
Han L, Zhang Q, Shi C, Leverson J, Dail M, Phillips DC, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour EJ, Kantarjian HM, Andreeff M, Sampath D, Konopleva M. Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models Blood. 126: 2544-2544. DOI: 10.1182/Blood.V126.23.2544.2544 |
0.49 |
|
| 2015 |
Battula VL, Le PM, Sun J, Mu H, Mc.Queen T, Shpall EJ, Konopleva M, Bueso-Ramos CE, Harrington M, Palisch CW, Andreeff M. Acute Myeloid Leukemia (AML) Cells Alter the Bone Marrow Microenvironment By Inducing Osteogenic and Suppressing Adipogenic Differentiation of MSCs through BMP-RUNX2-CTGF Mediated Mechanisms Blood. 126: 2403-2403. DOI: 10.1182/Blood.V126.23.2403.2403 |
0.432 |
|
| 2015 |
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen J, Wang Z, Ma W, Lee H, Orlowski RZ, ... ... Andreeff M, et al. ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response Blood. 126: 2051-2051. DOI: 10.1182/Blood.V126.23.2051.2051 |
0.465 |
|
| 2015 |
Zhou H, Mak PY, Mu H, Mak D, Zeng Z, Cortes J, Andreeff M, Carter BZ. Synergistic Effects of Combined Targeting of Beta-Catenin/CBP and Bcr-Abl in CML Blast Crisis Stem/Progenitor Cells in Vitro and in Vivo as Analyzed By Single Cell Mass Cytometry (CyTOF) Blood. 126: 1566-1566. DOI: 10.1182/Blood.V126.23.1566.1566 |
0.417 |
|
| 2015 |
Zeng Z, Liu W, Tsao T, Qiu Y, Samudio I, Baggerly K, Kornblau SM, Kantarjian HM, Andreeff M, Konopleva M. Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML Blood. 126: 1398-1398. DOI: 10.1182/Blood.V126.23.1398.1398 |
0.397 |
|
| 2015 |
Jacamo RO, Mu H, Zhang Q, Chachad D, Zhiqiang W, Ma W, Zhang M, Mak PY, Mak D, Ruvolo P, McQueen T, Lowe S, Zuber J, Eulberg D, Kruschinski A, ... ... Andreeff M, et al. Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia Blood. 126: 1348-1348. DOI: 10.1182/Blood.V126.23.1348.1348 |
0.434 |
|
| 2015 |
KC B, Kantarjian HM, Garcia-Manero G, Daver N, Borthakur G, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes JE. Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis Blood. 126: 1313-1313. DOI: 10.1182/Blood.V126.23.1313.1313 |
0.311 |
|
| 2015 |
Zhang W, Ishizawa J, Mu H, Daver N, Ruvolo V, Andreeff M. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias Blood. 126: 1266-1266. DOI: 10.1182/Blood.V126.23.1266.1266 |
0.404 |
|
| 2015 |
Ruvolo P, Qiu Y, Ruvolo V, Wang R, Zeng Z, Burks J, Pan R, Hail N, McQueen T, Yoo S, Kornblau SM, Andreeff M. Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment Blood. 126: 1198-1198. DOI: 10.1182/Blood.V126.23.1198.1198 |
0.476 |
|
| 2015 |
Battula VL, Le PM, Sun J, Benton CB, Queen TM, Shpall EJ, Bueso-Ramos CE, Konopleva M, Andreeff M. Abstract 5085: Acute myeloid leukemia cells induce osteogenic differentiation in mesenchymal stem cells through bone morphogenetic protein- and RUNX-2- mediated signaling Cancer Research. 75: 5085-5085. DOI: 10.1158/1538-7445.Am2015-5085 |
0.406 |
|
| 2015 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M, Garnett M, Benes C. Abstract 4475: In vitro efficacy profiling of ONC201 in cancer cells reveals sensitivity pattern that is consistent with ER stress response Cancer Research. 75: 4475-4475. DOI: 10.1158/1538-7445.Am2015-4475 |
0.365 |
|
| 2015 |
Kojima K, Nishida Y, Maeda A, Chachad D, Kitamura H, Ishizawa J, Andreeff M, Kimura S. Abstract 2938: BMI-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells Cancer Research. 75: 2938-2938. DOI: 10.1158/1538-7445.Am2015-2938 |
0.45 |
|
| 2015 |
Battula VL, Sun J, Hortobagyi GN, Andreeff M. Abstract 1528: GD2+ breast cancer stem cell growth is dependent on NFκB signaling and suppressed by the IKK inhibitor BMS345541 in vitro and in vivo Cancer Research. 75: 1528-1528. DOI: 10.1158/1538-7445.Am2015-1528 |
0.416 |
|
| 2015 |
Sun J, Hortobagyi GN, Andreeff M, Battula VL. Abstract 1421: The spontaneous generation of GD2+ breast cancer stem-like cells is directly proportional to tumor progression and mediated by epithelial to mesenchymal transition and NFκB activation Cancer Research. 75: 1421-1421. DOI: 10.1158/1538-7445.Am2015-1421 |
0.406 |
|
| 2015 |
Benton CB, Rawi AA, Min T, Wang R, Schober W, Wang Z, Zeng Z, Hokanson J, Zhu Z, Su X, Zheng X, Lu K, Carter B, Davis RE, Kantarjian H, ... ... Andreeff M, et al. Abstract 1391: Single cell analysis of Lin-CD34-CD45- cells from primary AML samples reveals leukemia clones with stem cell-like properties distinct from CD34+CD38-CD123+ LSC Cancer Research. 75: 1391-1391. DOI: 10.1158/1538-7445.Am2015-1391 |
0.323 |
|
| 2015 |
Konopleva MY, Zal T, Millward NMZ, Cho B, Harutyunyan K, Zal A, Mu H, Konoplev S, Benito J, Velez J, Bueso-Ramso C, Molina J, Bhattacharya PK, Francesco MED, Marszalek J, ... Andreeff M, et al. Abstract PL07-01: Altered metabolism in leukemic microenvironment Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Pl07-01 |
0.473 |
|
| 2015 |
Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Tse A, Rao A, Andreeff M. Abstract B1: Gene expression and TP53 mutation analysis predict sensitivity of leukemia cells to MDM2 inhibition by DS-3032b Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B1 |
0.368 |
|
| 2015 |
Ruvolo PP, Ruvolo V, Hail N, Schober W, Andreeff M. Targeting Galectin As A Strategy To Improve BH3 Mimetic Efficacy For The Therapy Of Acute Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S79. DOI: 10.1016/J.Clml.2015.07.161 |
0.485 |
|
| 2015 |
Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting of Bcl-2 and Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem/Progenitor Cells Clinical Lymphoma Myeloma and Leukemia. 15: S34. DOI: 10.1016/J.Clml.2015.07.070 |
0.386 |
|
| 2015 |
Benton CB, Ruvolo VR, Konopleva M, Palla SL, Nogueras-Gonzalez G, McQueen T, Kornblau SM, Andreeff M, Ruvolo PP. Expression of differential protein phosphatase 2A subunit isoforms correlates with survival in acute myeloid leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S22. DOI: 10.1016/J.Clml.2015.07.049 |
0.306 |
|
| 2015 |
Ruvolo PP, Wang R, Ruvolo V, Zeng Z, Qiu Y, Pierce SA, McQueen T, Kornblau SM, Andreeff M. Proteomic Profiling Identifies Distinct Bone Marrow Niche Mesenchymal Stem Cell Populations In AML Patients Clinical Lymphoma Myeloma and Leukemia. 15: S19. DOI: 10.1016/J.Clml.2015.07.042 |
0.35 |
|
| 2015 |
Abraham M, Al-Rawi A, Pereg Y, Klein S, Wald H, Eizenberg O, Bulvik B, Russovsky L, Vainstein A, Aharon A, McQueen T, Pemmaraju N, Cortes J, Peled A, Borthakur G, ... Andreeff M, et al. BL-8040, A novel CXCR4 inhibitor, affects AML blasts survival and induces their terminal differentiation Clinical Lymphoma Myeloma and Leukemia. 15: S12. DOI: 10.1016/J.Clml.2015.07.029 |
0.339 |
|
| 2015 |
George B, Cortes J, Cabrero M, Jain N, Konopleva M, Andreeff M, Tapan K, Pierce S, Dellasala S, Borthakur G, Jabbour E, Garcia-Manero G, Kantarjian H, Ravandi F. Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia Clinical Lymphoma Myeloma and Leukemia. 15: S196-S197. DOI: 10.1016/J.Clml.2015.04.050 |
0.346 |
|
| 2015 |
Battula VL, Le PM, Sun J, Queen TM, Somanchi A, Wang R, Strunk D, Shpall EJ, Ruvolo P, Kantarjian H, Konopleva M, Andreeff M. Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance Clinical Lymphoma Myeloma and Leukemia. 15: S185-S186. DOI: 10.1016/J.Clml.2015.04.031 |
0.398 |
|
| 2015 |
Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Qiu Y, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. Tumor Suppressor Role for B55 alpha PP2A Isoform in AML Clinical Lymphoma Myeloma and Leukemia. 15: S180-S181. DOI: 10.1016/J.Clml.2015.04.024 |
0.408 |
|
| 2015 |
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, et al. Minimal Residual Disease By PCR Testing Is a Significant Predictor of Disease Relapse in Patients with FLT3 Positive AML after Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 21: S81-S82. DOI: 10.1016/J.Bbmt.2014.11.095 |
0.329 |
|
| 2014 |
Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, López C, Barreto A, Cardozo C, Palacios P, Morales L, Duque JE, Carmona JU, Konopleva M, Andreeff M, Samudio I. Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 7: 79-90. PMID 25112275 DOI: 10.1007/S12307-014-0149-3 |
0.331 |
|
| 2014 |
Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, Yan M, Hemachandran S, Pathak S, Zhou XJ, Andreeff M, Mohan C. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis & Rheumatology (Hoboken, N.J.). 66: 3129-39. PMID 25047252 DOI: 10.1002/Art.38782 |
0.338 |
|
| 2014 |
Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. British Journal of Haematology. 166: 862-74. PMID 24942980 DOI: 10.1111/Bjh.12978 |
0.413 |
|
| 2014 |
Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, ... ... Andreeff M, et al. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochimica Et Biophysica Acta. 1843: 1969-77. PMID 24858343 DOI: 10.1016/J.Bbamcr.2014.05.006 |
0.336 |
|
| 2014 |
Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Science. 105: 795-801. PMID 24766216 DOI: 10.1111/Cas.12430 |
0.383 |
|
| 2014 |
Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opinion On Investigational Drugs. 23: 943-54. PMID 24749672 DOI: 10.1517/13543784.2014.911839 |
0.333 |
|
| 2014 |
Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 13: 1848-59. PMID 24739393 DOI: 10.1158/1535-7163.Mct-13-0576 |
0.415 |
|
| 2014 |
Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2363-74. PMID 24619500 DOI: 10.1158/1078-0432.Ccr-13-2052 |
0.336 |
|
| 2014 |
Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemotherapy and Pharmacology. 73: 961-74. PMID 24619497 DOI: 10.1007/S00280-014-2428-6 |
0.323 |
|
| 2014 |
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, ... ... Andreeff M, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood. 123: 2691-702. PMID 24599548 DOI: 10.1182/Blood-2013-06-511527 |
0.435 |
|
| 2014 |
Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, ... ... Andreeff M, et al. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. The Journal of Clinical Investigation. 124: 1512-24. PMID 24590286 DOI: 10.1172/Jci70921 |
0.397 |
|
| 2014 |
Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, et al. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2226-35. PMID 24583795 DOI: 10.1158/1078-0432.Ccr-13-1978 |
0.359 |
|
| 2014 |
Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. Journal of the National Cancer Institute. 106: djt440. PMID 24526787 DOI: 10.1093/Jnci/Djt440 |
0.432 |
|
| 2014 |
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, ... ... Andreeff M, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discovery. 4: 362-75. PMID 24346116 DOI: 10.1158/2159-8290.Cd-13-0609 |
0.416 |
|
| 2014 |
Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis : An International Journal On Programmed Cell Death. 19: 698-707. PMID 24337870 DOI: 10.1007/s10495-013-0954-z |
0.359 |
|
| 2014 |
Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Annals of Hematology. 93: 485-92. PMID 24154679 DOI: 10.1007/S00277-013-1939-2 |
0.433 |
|
| 2014 |
Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematologica. 131: 59-69. PMID 24052005 DOI: 10.1159/000353164 |
0.387 |
|
| 2014 |
Takahashi K, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Dinardo CD, Jabbour E, Konopleva M, Andreeff M, Cortes JE. Propensity score matched comparison of intermediate-intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age ≥ 60) with acute myeloid leukemia (AML). Journal of Clinical Oncology. 32: 7097-7097. DOI: 10.1200/Jco.2014.32.15_Suppl.7097 |
0.319 |
|
| 2014 |
Andreeff M, Borthakur G, Zeng Z, Kelly MA, Wang R, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, et al. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. Journal of Clinical Oncology. 32: 7033-7033. DOI: 10.1200/Jco.2014.32.15_Suppl.7033 |
0.402 |
|
| 2014 |
Borthakur G, Nagler A, Ofran Y, Rowe JM, Altman JK, Frankfurt O, Tallman MS, Avivi I, Peled A, Pereg Y, Foley-Comer A, Russovsky L, Aharon A, McQueen T, Pemmaraju N, ... ... Andreeff M, et al. BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial Blood. 124: 950-950. DOI: 10.1182/Blood.V124.21.950.950 |
0.44 |
|
| 2014 |
Badar T, Kantarjian HM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Ravandi F, Cortes JE. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade Blood. 124: 949-949. DOI: 10.1182/Blood.V124.21.949.949 |
0.336 |
|
| 2014 |
Thomas DA, O'Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, et al. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL) Blood. 124: 940-940. DOI: 10.1182/Blood.V124.21.940.940 |
0.335 |
|
| 2014 |
Tabe Y, Harada M, Miyamae Y, Matsushita H, Kojima K, Fujimura T, Kazuno S, Ueno T, Miida T, Konopleva M, Andreeff M. The mTOR Kinase Inhibitor AZD-2014 Effectively Reverses XPO1/CRM1 Antagonist KPT-185–induced Glycolysis / Gluconeogenesis, Enhancing Antitumor Effects in Mantle Cell Lymphoma Blood. 124: 925-925. DOI: 10.1182/Blood.V124.21.925.925 |
0.39 |
|
| 2014 |
Davis RE, Ruvolo VR, Wang Z, Ma W, Schober WD, Rolke J, Tidmarsh G, Andreeff M, Ruvolo PP. GCS-100 Induces Apoptosis of Acute Myeloid Leukemia Cells By Disrupting Galectin-Mediated Survival Signaling Blood. 124: 904-904. DOI: 10.1182/Blood.V124.21.904.904 |
0.491 |
|
| 2014 |
Piya S, Ruvolo VR, Ruvolo PP, Davis RE, Wang Z, McQueen T, Schober WD, Andreeff M, Borthakur G. Ablation of Autophagy-Related E1 Ligase Atg7 Primes Acute Myelogenous Leukemia Cells to Apoptosis, Sensitizes to Chemotherapy and Overcomes Stroma Mediated Protection Blood. 124: 901-901. DOI: 10.1182/Blood.V124.21.901.901 |
0.486 |
|
| 2014 |
Matre P, Protopopova M, Feng N, Gay J, Greer J, Velez J, Mu H, Lodi A, Tadi S, Sweeney S, Andreeff M, Tiziani S, DiFrancesco ME, Marszalek J, Konopleva M. Novel Nanomolar Potency Mitochondrial Complex I Inhibitor Iacs-1131 Selectively Kills Oxphos-Dependent AML Cells Blood. 124: 622-622. DOI: 10.1182/Blood.V124.21.622.622 |
0.453 |
|
| 2014 |
Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Huh YO, Abruzzo L, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau SM, Borthakur G, Nguyen M, Stingo F, Hu P, Fox P, et al. MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes Blood. 124: 5334-5334. DOI: 10.1182/Blood.V124.21.5334.5334 |
0.37 |
|
| 2014 |
Prabhu VV, Ishizawa J, Zhao D, Allen JE, Batchelor TT, Chi AS, Andreeff M, El-Deiry WS. ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples Blood. 124: 5219-5219. DOI: 10.1182/Blood.V124.21.5219.5219 |
0.399 |
|
| 2014 |
Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober WD, Leverson J, Zhang B, Bhatia R, Konopleva M, Cortes JE, Andreeff M. Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells Blood. 124: 512-512. DOI: 10.1182/Blood.V124.21.512.512 |
0.474 |
|
| 2014 |
Allen JE, Ishizawa J, El-Deiry WS, Andreeff M. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies Blood. 124: 4812-4812. DOI: 10.1182/Blood.V124.21.4812.4812 |
0.422 |
|
| 2014 |
Ruvolo PP, Battula VL, Qui Y, Ruvolo VR, Jacamo R, Zeng Z, Wang R, McQueen T, Rao A, Yoo S, Le PM, Hail N, Carter BZ, Kornblau SM, Andreeff M. Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling Blood. 124: 4376-4376. DOI: 10.1182/Blood.V124.21.4376.4376 |
0.394 |
|
| 2014 |
Zhou H, Mak PY, Mu H, Mak DH, Kouji H, Konopleva M, Cortes JE, Andreeff M, Carter BZ. Combination of Tyrosine Kinase Inhibitor with β-Catenin/CBP Modulator C82 Reverses TKI Resistance, Eradicates Quiescent CML Stem/Progenitors Cells, and Overcomes MSC-Associated Microenvironmental Protection Blood. 124: 401-401. DOI: 10.1182/Blood.V124.21.401.401 |
0.376 |
|
| 2014 |
Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo CD, Daver N, Majeti R, Andreeff M, Chan SM, Konopleva M. Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia Blood. 124: 3763-3763. DOI: 10.1182/Blood.V124.21.3763.3763 |
0.481 |
|
| 2014 |
Cho B, Zeng Z, Mu H, Wang Z, McQueen T, Protopopova M, Cortes JE, Marszalek J, Peng S, Davis RE, Thornton D, Andreeff M, Konopleva M. Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy Blood. 124: 3745-3745. DOI: 10.1182/Blood.V124.21.3745.3745 |
0.444 |
|
| 2014 |
Tabe Y, Harada M, Miyamae Y, Fujimura T, Kazuno S, Ueno T, Miida T, Andreeff M, Konopleva M. Metabolic Re-Programming in Notch-Activated T-ALL By mTOR Inhibitor AZD2014 Combined with L-Asparaginase Blood. 124: 3626-3626. DOI: 10.1182/Blood.V124.21.3626.3626 |
0.365 |
|
| 2014 |
Zeng Z, Wang R, Shi Y, Qiu Y, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, Kantarjian HM, Kornblau SM, Fruman D, Andreeff M, Konopleva M. MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Blood. 124: 3613-3613. DOI: 10.1182/Blood.V124.21.3613.3613 |
0.458 |
|
| 2014 |
Mak PY, Kornblau SM, Qiu Y, Wei W, Kouji H, Coombes K, Cortes JE, Andreeff M, Carter BZ. Disrupting Wnt/ß-Catenin Signaling By a ß-Catenin/CBP Modulator C-82 Suppresses Cell Growth and Induces Apoptosis in AML Blasts and CD34+38- AML Progenitor Cells Blood. 124: 3600-3600. DOI: 10.1182/Blood.V124.21.3600.3600 |
0.457 |
|
| 2014 |
Borthakur G, Foran JM, Wang ES, Rakkar A, Hager S, Frey NV, Andreeff M, Garcia-Manero G, Kadia TM, Carter BZ, Minderman H, Russell L, Tibes R. A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis Blood. 124: 3263-3263. DOI: 10.1182/Blood.V124.21.3263.3263 |
0.381 |
|
| 2014 |
Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, Allen JE, Neelapu SS, McDonnell TJ, Miranda RN, Kwak LW, ... ... Andreeff M, et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition Blood. 124: 3122-3122. DOI: 10.1182/Blood.V124.21.3122.3122 |
0.461 |
|
| 2014 |
Battula VL, Le PM, Sun J, McQueen T, Somanchi A, Wang R, Strunk D, Shpall EJ, Ruvolo PP, Kantarjian HM, Konopleva M, Andreeff M. Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2 Blood. 124: 2929-2929. DOI: 10.1182/Blood.V124.21.2929.2929 |
0.44 |
|
| 2014 |
Gallardo M, Lee HJ, Zhang X, Pageon LR, Multani A, Reschke M, Clohessy JG, Quintás-Cardama A, Andreeff M, Kornblau SM, Pandolfi PP, Post SM. hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression Blood. 124: 2382-2382. DOI: 10.1182/Blood.V124.21.2382.2382 |
0.344 |
|
| 2014 |
Tabe Y, Hatanaka Y, Ruvolo PP, Miida T, Kornblau SM, Andreeff M, Konopleva M. Pro-Survival Effects of TGF-β1 Are Associated with Molecular Signaling Changes of ERK, FLI-1, and CD44 in AML Cells Blood. 124: 2337-2337. DOI: 10.1182/Blood.V124.21.2337.2337 |
0.362 |
|
| 2014 |
Tabe Y, Harada M, Miyamae Y, Kazuno S, Fujimura T, Ueno T, Miida T, Konopleva M, Andreeff M. Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma Blood. 124: 2254-2254. DOI: 10.1182/Blood.V124.21.2254.2254 |
0.467 |
|
| 2014 |
Pan R, Kojima K, Zheng Z, Ruvolo VR, Nichols G, Leverson JD, Dangl M, Konopleva M, Andreeff M. Activation of p53 By Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199) Blood. 124: 2162-2162. DOI: 10.1182/Blood.V124.21.2162.2162 |
0.434 |
|
| 2014 |
Jacamo R, Ling X, Wang Z, Ma W, Zhang M, Ruvolo PP, Ruvolo VR, Lowe SW, Zuber J, Konopleva M, Davis RE, Andreeff M. AML Genotype-Specific and Non-Specific Regulation of Mesenchymal Stromal Cell Transcriptome in the Bone Marrow Microenvironment Blood. 124: 1586-1586. DOI: 10.1182/Blood.V124.21.1586.1586 |
0.449 |
|
| 2014 |
Pinnamaneni P, Jorgensen JL, Kantarjian HM, Jabbour E, Pierce SR, Brandt M, Wang SA, Konoplev S, Konopleva M, Kornblau SM, Kadia T, DiNardo CD, Pemmaraju N, Andreeff M, Estrov Z, et al. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia Blood. 124: 1015-1015. DOI: 10.1182/Blood.V124.21.1015.1015 |
0.339 |
|
| 2014 |
Tabe Y, Harada M, Miyamae Y, Mogushi K, Kazuno S, Fujimura T, Matsushita H, Ueno T, Yokomizo T, Miida T, Samudio I, Andreeff M, Konopleva M. Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signature Linking Transcription with Metabolic Changes That Contribute to Survival of Acute Monocytic Leukemia Cells Blood. 124: 1013-1013. DOI: 10.1182/Blood.V124.21.1013.1013 |
0.395 |
|
| 2014 |
Cho BS, Zeng Z, Mu H, McQueen T, Protopopova M, Cortes J, Marszalek J, Peng S, Thornton DE, Andreeff M, Konopleva M. Abstract 4768: Novel peptidic CXCR4 antagonist LY2510924 disrupts the SDF-1α/CXCR4 axis resulting in anti-AML efficacyin vivo Cancer Research. 74: 4768-4768. DOI: 10.1158/1538-7445.Am2014-4768 |
0.403 |
|
| 2014 |
Ishizawa J, Kojima K, Duvvuri SR, McQueen T, Ruvolo VR, Nogueras-Gonzalez GM, Huang X, Pierceall W, Cardone M, Lena R, Doykan C, Shacham S, Kauffman M, Konopleva M, Andreeff M. Abstract 340: Mitochondrial priming of new targeted agents in acute myeloid leukemia Cancer Research. 74: 340-340. DOI: 10.1158/1538-7445.Am2014-340 |
0.375 |
|
| 2014 |
Ciuffreda L, Falcone I, Matteoni S, Sacconi A, Malusa F, Luca TD, Incani UC, Curatolo AD, Konopleva M, Andreeff M, Eramo A, Maria RD, Bufalo DD, Cognetti F, Milella M. Abstract 2618: PTEN loss as a putative biomarker of synergistic growth inhibitory activity of combined MEK/ERK and PI3K/mTOR pathway blockade Cancer Research. 74: 2618-2618. DOI: 10.1158/1538-7445.Am2014-2618 |
0.396 |
|
| 2014 |
Benton C, Gu L, Qiu P, Kantarjian H, Ravandi F, Garcia-Manero G, Brandt M, Pierce S, Konopleva M, Cortes J, Andreeff M, Quintas-Cardama A. Therapy Related Cellular Changes as a Tool for Prognosis in AML Clinical Lymphoma Myeloma and Leukemia. 14: S120. DOI: 10.1016/J.Clml.2014.06.039 |
0.36 |
|
| 2014 |
Battula VL, Benito J, Somanchi AG, Duvvuri S, Hodgson L, Chen Y, Ma W, Davis RE, McNiece I, Shpall EJ, Konopleva M, Andreeff M. Acute Myeloid Leukemia Cells Acquire Stem Cell Features in the Bone Marrow Microenvironment Clinical Lymphoma Myeloma and Leukemia. 14: S119-S120. DOI: 10.1016/J.Clml.2014.06.038 |
0.394 |
|
| 2013 |
Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia. 13: 686-92. PMID 24035716 DOI: 10.1016/J.Clml.2013.05.013 |
0.33 |
|
| 2013 |
Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. Journal of Molecular Medicine (Berlin, Germany). 91: 1383-97. PMID 23955073 DOI: 10.1007/S00109-013-1076-3 |
0.417 |
|
| 2013 |
Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, et al. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 122: 2864-76. PMID 23943652 DOI: 10.1182/Blood-2012-07-445635 |
0.434 |
|
| 2013 |
Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Research. 73: 5347-59. PMID 23838935 DOI: 10.1158/0008-5472.Can-13-0087 |
0.463 |
|
| 2013 |
Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. Plos One. 8: e62785. PMID 23826077 DOI: 10.1371/journal.pone.0062785 |
0.349 |
|
| 2013 |
Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE, Konopleva M, Andreeff M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood. 122: 357-66. PMID 23741006 DOI: 10.1182/Blood-2012-06-437988 |
0.444 |
|
| 2013 |
Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. The Journal of Clinical Investigation. 123: 2395-407. PMID 23676502 DOI: 10.1172/Jci66553 |
0.315 |
|
| 2013 |
Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells Leukemia Research. 37: 974-979. PMID 23669290 DOI: 10.1016/J.Leukres.2013.04.018 |
0.377 |
|
| 2013 |
Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, ... ... Andreeff M, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 121: 4655-62. PMID 23613521 DOI: 10.1182/Blood-2013-01-480228 |
0.301 |
|
| 2013 |
Russell KC, Tucker HA, Bunnell BA, Andreeff M, Schober W, Gaynor AS, Strickler KL, Lin S, Lacey MR, O'Connor KC. Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells. Tissue Engineering. Part A. 19: 2253-66. PMID 23611563 DOI: 10.1089/Ten.Tea.2012.0649 |
0.378 |
|
| 2013 |
Vélez J, Hail N, Konopleva M, Zeng Z, Kojima K, Samudio I, Andreeff M. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Frontiers in Oncology. 3: 67. PMID 23565503 DOI: 10.3389/Fonc.2013.00067 |
0.351 |
|
| 2013 |
Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, ... Andreeff M, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 121: 4166-4174. PMID 23564911 DOI: 10.1182/Blood-2012-08-447581 |
0.378 |
|
| 2013 |
Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N, Konopleva M, Andreeff M. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. Plos One. 8: e58426. PMID 23484027 DOI: 10.1371/Journal.Pone.0058426 |
0.392 |
|
| 2013 |
Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Investigational New Drugs. 31: 1023-34. PMID 23397500 DOI: 10.1007/S10637-013-9935-X |
0.372 |
|
| 2013 |
Shinojima N, Hossain A, Takezaki T, Fueyo J, Gumin J, Gao F, Nwajei F, Marini FC, Andreeff M, Kuratsu J, Lang FF. TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Research. 73: 2333-44. PMID 23365134 DOI: 10.1158/0008-5472.Can-12-3086 |
0.42 |
|
| 2013 |
Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Research. 73: 1037-45. PMID 23345162 DOI: 10.1158/0008-5472.Can-12-3678 |
0.419 |
|
| 2013 |
Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M, Marini FC. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 15: 20-32. PMID 23260083 DOI: 10.1016/J.Jcyt.2012.10.003 |
0.726 |
|
| 2013 |
Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Letters. 329: 45-58. PMID 23036488 DOI: 10.1016/j.canlet.2012.09.020 |
0.305 |
|
| 2013 |
Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia Leukemia and Lymphoma. 54: 138-144. PMID 22691121 DOI: 10.3109/10428194.2012.701739 |
0.302 |
|
| 2013 |
Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Correction: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression (PLoS ONE) Plos One. 8. DOI: 10.1371/annotation/4ab4c130-16cb-41f0-9507-b00ce070fbc6 |
0.707 |
|
| 2013 |
Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Ravandi F, Kadia TM, Andreeff M, Cortes JE, Hoberman K, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 31: 7029-7029. DOI: 10.1200/Jco.2013.31.15_Suppl.7029 |
0.417 |
|
| 2013 |
Pierceall WE, Carlson NE, Richard DJ, Huang X, Elaschoff M, Konopleva M, Kornblau SM, Cardone MH, Andreeff M. BH3 profiling as a predictive biomarker for response to cytarabine-based treatment of acute myelogenous leukemia. Journal of Clinical Oncology. 31: 7017-7017. DOI: 10.1200/Jco.2013.31.15_Suppl.7022 |
0.368 |
|
| 2013 |
Tabe Y, Kojima K, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Andreeff M. Molecular Mechanisms Of Inhibition Of Ribosomal Biogenesis and Translational Flux By The Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist KPT-185 In Mantle Cell Lymphoma Blood. 122: 820-820. DOI: 10.1182/Blood.V122.21.820.820 |
0.404 |
|
| 2013 |
Matre P, Samudio I, Jacamo R, Wang Y, Wang J, Davis RE, Su X, Schindela S, Newman R, Hu J, Haferlach T, Andreeff M, Flores ER, Schimmer A, Konopleva M. Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias Blood. 122: 606-606. DOI: 10.1182/Blood.V122.21.606.606 |
0.455 |
|
| 2013 |
Tabe Y, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Andreeff M, Konopleva M, Kimura S. Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling Blood. 122: 3991-3991. DOI: 10.1182/Blood.V122.21.3991.3991 |
0.438 |
|
| 2013 |
Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo VR, Andreeff M. ARC Supports Leukemia-Stromal Interactions By Regulating Multiple Receptor-Chemokine Axes In AML Blood. 122: 3947-3947. DOI: 10.1182/Blood.V122.21.3947.3947 |
0.444 |
|
| 2013 |
Konopleva M, Handisides DR, Richie MA, Benito JM, Borthakur G, Jabbour EJ, Faderl SH, Cortes JE, Kroll S, Andreeff M, Kantarjian HM, Thomas DA. A Phase 1 Study of TH-302, an Investigational Hypoxia-Targeted Drug, in Patients with Advanced Leukemias Blood. 122: 3920-3920. DOI: 10.1182/Blood.V122.21.3920.3920 |
0.311 |
|
| 2013 |
Konopleva M, Benito JM, Harutyunyan KG, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy JC, Bendall LJ, Zweidler-McKay PA, Coombes KR, Qiu Y, ... ... Andreeff M, et al. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 Blood. 122: 3919-3919. DOI: 10.1182/Blood.V122.21.3919.3919 |
0.429 |
|
| 2013 |
Tabe Y, Jin L, Kazuno S, Fujimura T, Matsushita H, Ueno T, Miida T, Andreeff M, Konopleva M. Molecular Mechanisms Of Adipocyte-Leukemia Interactions Revealed By The Quantitative Proteomics Technology: Pro-Survival Function Of Adipocyte-Derived Free Fatty Acids On Acute Monoblastic Leukemia Mitochondrial Biogenesis Blood. 122: 3881-3881. DOI: 10.1182/Blood.V122.21.3881.3881 |
0.424 |
|
| 2013 |
Yoshimura M, Ishizawa J, Dilip A, Shacham S, Kauffman M, Tabe Y, Kimura S, Andreeff M, Kojima K. Induction Of p53 Transcription and Apoptosis By XPO1 Inhibition In Mantle Cell Lymphoma Blood. 122: 3825-3825. DOI: 10.1182/Blood.V122.21.3825.3825 |
0.41 |
|
| 2013 |
Ishizawa J, Kojima K, Dilip A, Ruvolo VR, Carter BZ, Allen JE, Neelapu SS, McDonnell TJ, Talekar MK, El-Deiry WS, Kwak LW, Andreeff M. ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas Blood. 122: 3822-3822. DOI: 10.1182/Blood.V122.21.3822.3822 |
0.426 |
|
| 2013 |
Tabe Y, Jin L, Hatanaka Y, Matsushita H, Kazuno S, Fujimura T, Ueno T, Sasai K, Iwabuchi K, Andreeff M, Konopleva M, Miida T. Integrative Genomic and Proteomic Analysis Of Low-Dose ionizing Irradiation Effects On Bone Marrow Stromal Microenvironment and On Survival Of Pre-Leukemic Cells Blood. 122: 3775-3775. DOI: 10.1182/Blood.V122.21.3775.3775 |
0.435 |
|
| 2013 |
Andreeff M, Wang R, Davis RE, Jacamo R, Ruvolo PP, McQueen T, Huang X, Battula VL, Chen Y, Majumdar S, Benito JM, Zeng Z, Benton CB, Carter BZ, Mu H, et al. Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo Blood. 122: 3685-3685. DOI: 10.1182/Blood.V122.21.3685.3685 |
0.456 |
|
| 2013 |
Han L, Jorgensen JL, Wang SA, Huang X, Nogueras González GM, Brooks C, Rowinsky E, Levis M, Zhou J, Ciurea SO, Alatrash G, Cortes JE, Kantarjian HM, Andreeff M, Ravandi F, et al. Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations Blood. 122: 359-359. DOI: 10.1182/Blood.V122.21.359.359 |
0.345 |
|
| 2013 |
Ishizawa J, Sugihara E, Hashimoto N, Kuninaka S, Kojima K, Andreeff M, Okamoto S, Saya H. Loss of Function of The Cell Cycle Regulator Cdh1 Causes Cell Fragility due to Aberrant G2/M Checkpoint and Develops Resistant Disease in a B-ALL/LBL Mouse Model Blood. 122: 344-344. DOI: 10.1182/Blood.V122.21.344.344 |
0.409 |
|
| 2013 |
Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo VR, Jacamo R, Andreeff M, Carter BZ. ARC Suppresses Cell Death By Antagonizing p53 Function and Suppressing TRAIL In AML Cells Blood. 122: 2688-2688. DOI: 10.1182/Blood.V122.21.2688.2688 |
0.441 |
|
| 2013 |
Zhang W, Borthakur G, Gao C, Chen Y, Lan YS, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation Blood. 122: 2683-2683. DOI: 10.1182/Blood.V122.21.2683.2683 |
0.421 |
|
| 2013 |
Shah SS, Kantarjian HM, Ravandi F, O'Brien S, Garcia-Manero G, Andreeff M, Konopleva M, Jabbour E, Pierce SR, Borthakur G, Cortes JE. Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy Blood. 122: 2654-2654. DOI: 10.1182/Blood.V122.21.2654.2654 |
0.348 |
|
| 2013 |
Benton CB, Gu L, Kantarjian HM, Qiu P, Ravandi F, Garcia-Manero G, Pierce S, Brandt M, Konopleva M, Cortes JE, Andreeff M, Quintas-Cardama A. Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status Blood. 122: 2584-2584. DOI: 10.1182/Blood.V122.21.2584.2584 |
0.332 |
|
| 2013 |
Ruvolo PP, Wang R, Ruvolo VR, Jacamo R, McQueen T, Borthakur G, Qiu Y, Coombes KR, Zhang N, Shpall EJ, Champlin RE, Garzon R, Marcucci G, Croce CM, Konopleva M, ... Andreeff M, et al. Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells Blood. 122: 2551-2551. DOI: 10.1182/Blood.V122.21.2551.2551 |
0.45 |
|
| 2013 |
Battula VL, Benito JM, Somanchi A, Duvvuri S, Hodgson L, Chen Y, Ma W, Davis RE, McNiece IK, Shpall EJ, Konopleva M, Andreeff M. Bone Marrow Microenvironment Induces Stem Cell-Like Phenotype In Acute Myeloid Leukemia Blood. 122: 2457-2457. DOI: 10.1182/Blood.V122.21.2457.2457 |
0.439 |
|
| 2013 |
Jacamo R, Zeng Z, Chen Y, Shi Y, McQueen T, Kruschinski A, Konopleva M, Ruvolo PP, Andreeff M. SDF-1 Inhibition Using Spiegelmer® Nox-A12 As a Novel Strategy For Targeting AML Cells Within Their BM Microenvironment Blood. 122: 2454-2454. DOI: 10.1182/Blood.V122.21.2454.2454 |
0.459 |
|
| 2013 |
Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, Jones RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, ... ... Andreeff M, et al. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant Blood. 122: 2083-2083. DOI: 10.1182/Blood.V122.21.2083.2083 |
0.37 |
|
| 2013 |
Carter BZ, Mak PY, Mak DH, Konopleva M, Cortes J, Andreeff M. Activation Of p53 By MDM2-Inhibition Sensitizes Quiescent Blast Crisis CML Stem/Progenitor Cells To Bcl-2 Inhibitor- and Tyrosine Kinase Inhibitor-Induced Cell Death Blood. 122: 1476-1476. DOI: 10.1182/Blood.V122.21.1476.1476 |
0.448 |
|
| 2013 |
Pan R, Debose L, Benito JM, Golfman LS, Zweidler-McKay PA, Han L, Harutyunyan KG, Mu H, Ruvolo VR, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian HM, Ruvolo PP, ... Andreeff M, et al. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia Blood. 122: 1456-1456. DOI: 10.1182/Blood.V122.21.1456.1456 |
0.486 |
|
| 2013 |
Nazha A, Kantarjian HM, Ravandi F, Xuelin H, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, et al. Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML) Blood. 122: 1451-1451. DOI: 10.1182/Blood.V122.21.1451.1451 |
0.317 |
|
| 2013 |
Han L, Zeng Z, Qiu P, Jorgensen JL, Mak DH, Burks JK, McQueen T, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission Blood. 122: 1311-1311. DOI: 10.1182/Blood.V122.21.1311.1311 |
0.373 |
|
| 2013 |
Tabe Y, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Weinstock DM, Thomas DA, Andreeff M, Konopleva M. Efficacy and Mechanisms Of The mTOR Inhibitor AZD2014 Combined With L-Asparaginase Or JAK2 Inhibitor TG101348 In ALL Blood. 122: 1282-1282. DOI: 10.1182/Blood.V122.21.1282.1282 |
0.425 |
|
| 2013 |
Konopleva MY, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Ruvolo P, Huang X, Kadia T, Feliu J, Burger JA, Andreeff M, Liu W, Kornblau SM, Baggerly K, et al. Abstract LB-293: Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in second relapse. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-293 |
0.411 |
|
| 2013 |
Pan R, Ruvolo V, Pellecchia M, Wei J, Konopleva M, Reed JC, Ruvolo P, Andreeff M. Abstract 605: Apogossypolone derivative -BI97D6 effectively targets MCL1 overexpressing Acute Myeloid Leukemia cells. Cancer Research. 73: 605-605. DOI: 10.1158/1538-7445.Am2013-605 |
0.484 |
|
| 2013 |
Ruvolo PP, Ruvolo V, Jacamo R, Qiu Y, Coombes K, Zhang N, Garzon R, Kornblau SM, Croce C, Andreeff M. Abstract 4120: Low expression of PP2A/B55α is associated with increased MiR-191 expression and relapse in acute myeloid leukemia. Cancer Research. 73: 4120-4120. DOI: 10.1158/1538-7445.Am2013-4120 |
0.311 |
|
| 2013 |
Battula VL, Chen Y, Yang F, Konopleva M, Andreeff M. Abstract 2606: Bone marrow microenvironment contributes to stem cell phenotype in acute myeloid leukemia. Cancer Research. 73: 2606-2606. DOI: 10.1158/1538-7445.Am2013-2606 |
0.405 |
|
| 2013 |
Richard DJ, Carlson N, Pierceall W, Lena R, Bannister T, Hodder P, Spicer T, Andreeff M, Opferman J, Koss B, Kung A, Cardone M. Abstract 2466: Characterization and development of on-target Mcl-1 inhibitors; BH3 profiling provides a valuable drug discovery tool. Cancer Research. 73: 2466-2466. DOI: 10.1158/1538-7445.Am2013-2466 |
0.402 |
|
| 2013 |
Matre P, Jacamo RO, Wang Y, Wang J, Davis RE, Andreeff M, Schimmer AD, Konopleva M. Abstract 1887: Bone marrow-derived stromal cells and hypoxia promote glutamine dependency in leukemias. Cancer Research. 73: 1887-1887. DOI: 10.1158/1538-7445.Am2013-1887 |
0.35 |
|
| 2013 |
Borthakur G, Duvvuri S, Lan Y, Ruvolo V, Ruvolo P, Qiu Y, Konopleva M, Kornblau S, Andreeff M. Abstract 1666: Targeting autophagy-related E1 ligase Atg7 increases chemosensitivity in acute myelogenous leukemia cells and overcomes stroma mediated resistance. Cancer Research. 73: 1666-1666. DOI: 10.1158/1538-7445.Am2013-1666 |
0.456 |
|
| 2013 |
Benito JM, Lu H, Shi Y, Jacamo RO, McQueen TJ, Konoplev S, Bueso-Ramos C, Zweidler-McKay P, Handisides D, Hart CP, Andreeff M, Konopleva M. Hypoxia Activated Pro-Drug TH-302 Induces Hypoxia-Dependent Anti-leukemia Activity in vitro and in vivo Clinical Lymphoma Myeloma and Leukemia. 13: S377. DOI: 10.1016/J.Clml.2013.07.083 |
0.473 |
|
| 2013 |
Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Kornblau S, McQueen T, Weng D, Burns J, Andreeff M. Antagonizing IAPs by SMAC Mimetic Birinapant Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination With Chemotherapy in vitro and in vivo Clinical Lymphoma Myeloma and Leukemia. 13: S376-S377. DOI: 10.1016/J.Clml.2013.07.082 |
0.383 |
|
| 2012 |
Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, Konopleva M, Andreeff M. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 27: 1358-68. PMID 23247046 DOI: 10.1182/Blood.V112.11.311.311 |
0.406 |
|
| 2012 |
Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, ... ... Andreeff M, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews. Cancer. 12: 767-75. PMID 23051844 DOI: 10.1038/Nrc3368 |
0.35 |
|
| 2012 |
Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Rohban R, Etchart N, Fruehwirth M, Beham-Schmid C, Andreeff M, Strunk D. Oxygen sensing mesenchymal progenitors promote neo-vasculogenesis in a humanized mouse model in vivo. Plos One. 7: e44468. PMID 22970226 DOI: 10.1371/Journal.Pone.0044468 |
0.359 |
|
| 2012 |
Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Annals of Hematology. 91: 1861-70. PMID 22893484 DOI: 10.1007/S00277-012-1537-8 |
0.419 |
|
| 2012 |
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120: 2679-89. PMID 22826565 DOI: 10.1182/Blood-2011-11-393934 |
0.44 |
|
| 2012 |
Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, ... ... Andreeff M, et al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biology & Therapy. 13: 858-70. PMID 22785211 DOI: 10.4161/Cbt.20838 |
0.416 |
|
| 2012 |
Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells. Anticancer Research. 32: 2871-80. PMID 22753750 |
0.31 |
|
| 2012 |
Liopo AV, Conjusteau A, Konopleva M, Andreeff M, Oraevsky AA. Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles. Nano Biomedicine and Engineering. 4: 66-75. PMID 22720194 DOI: 10.5101/Nbe.V4I2.P66-75 |
0.353 |
|
| 2012 |
Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, Konopleva M, Andreeff M, Lee MH, Yeung SC. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle (Georgetown, Tex.). 11: 2314-26. PMID 22659796 DOI: 10.4161/Cc.20770 |
0.375 |
|
| 2012 |
Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 120: 173-80. PMID 22645176 DOI: 10.1182/Blood-2012-02-409888 |
0.454 |
|
| 2012 |
Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3396-406. PMID 22634319 DOI: 10.1158/1078-0432.Ccr-11-2703 |
0.304 |
|
| 2012 |
Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. The Journal of Clinical Investigation. 122: 2066-78. PMID 22585577 DOI: 10.1172/Jci59735 |
0.423 |
|
| 2012 |
Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood. 119: 4971-80. PMID 22490334 DOI: 10.1182/Blood-2011-11-389957 |
0.378 |
|
| 2012 |
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, ... ... Andreeff M, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. Journal of Molecular Medicine (Berlin, Germany). 90: 1133-44. PMID 22399013 DOI: 10.1007/S00109-012-0886-Z |
0.392 |
|
| 2012 |
Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. Plos One. 7: e30563. PMID 22363446 DOI: 10.1371/Journal.Pone.0030563 |
0.369 |
|
| 2012 |
Bernstein SH, Venkatesh S, Li M, Lee J, Lu B, Hilchey SP, Morse KM, Metcalfe HM, Skalska J, Andreeff M, Brookes PS, Suzuki CK. The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives. Blood. 119: 3321-9. PMID 22323447 DOI: 10.1182/Blood-2011-02-340075 |
0.382 |
|
| 2012 |
Xu-Monette ZY, Jeffrey Medeiros L, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies Blood. 119: 3668-3683. PMID 22275381 DOI: 10.1182/Blood-2011-11-366062 |
0.356 |
|
| 2012 |
Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex Leukemia. 26: 778-787. PMID 22064351 DOI: 10.1038/Leu.2011.287 |
0.339 |
|
| 2012 |
Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. 118: 2665-73. PMID 22020636 DOI: 10.1002/Cncr.26580 |
0.341 |
|
| 2012 |
Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737 Cancer. 118: 1023-1031. PMID 21761401 DOI: 10.1002/Cncr.26360 |
0.405 |
|
| 2012 |
Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 31: 68-79. PMID 21643014 DOI: 10.1038/Onc.2011.213 |
0.366 |
|
| 2012 |
Kobayashi T, Clodi K, Yang Y, Ruan S, Shiku H, Andreeff M, Shay J, Zhang W. Inhibition of telomerase activity correlates with a decrease in the RNA component of telomerase during differentiation. International Journal of Oncology. 11: 13-7. PMID 21528174 DOI: 10.3892/Ijo.11.1.13 |
0.397 |
|
| 2012 |
Andreeff M, Zeng Z, Kelly MA, Wang R, McQueen TJ, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian H, Konopleva M. Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib. Journal of Clinical Oncology. 30: TPS6635-TPS6635. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps6635 |
0.404 |
|
| 2012 |
Benton CB, Ravandi F, Andreeff M, Kantarjian H, Konopleva M. AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series. Journal of Clinical Oncology. 30: 6576-6576. DOI: 10.1200/Jco.2012.30.15_Suppl.6576 |
0.341 |
|
| 2012 |
Gorombei P, Stephanie B, Omidvar N, Patricia K, Carole LP, de la Grange P, Christophe L, Janin A, Maria-Elena N, Konopleva M, Andreeff M, Marika P, Robert W, Fenaux P, Chomienne C, et al. BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS Blood. 120: 678-678. DOI: 10.1182/Blood.V120.21.678.678 |
0.405 |
|
| 2012 |
Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Kojima K, Geho D, Blotner S, et al. Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia Blood. 120: 675-675. DOI: 10.1182/Blood.V120.21.675.675 |
0.406 |
|
| 2012 |
Hofmann NA, Ortner A, Jacamo R, Reinisch A, Schallmoser K, Rohban R, Frühwirth M, Liechtenstein N, Beham-Schmid C, Linkesch W, Andreeff M, Strunk D. A Novel Role for Mesenchymal Stem/Progenitor Cells As Hypoxia Sensors During Initiation of Neo-Vasculogenesis in Vivo Blood. 120: 613-613. DOI: 10.1182/Blood.V120.21.613.613 |
0.347 |
|
| 2012 |
Carter BZ, Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML Blood. 120: 534-534. DOI: 10.1182/Blood.V120.21.534.534 |
0.448 |
|
| 2012 |
Tabe Y, Jin L, Kazuno S, Fujimura T, Matsushita H, Ueno T, Andreeff M, Gutterman JU, Konopleva M. A Plant Triterpenoid Avicin D Stimulates Adipocytic Differentiation of Bone Marrow Stromal Cells and Promotes Their Pro-Survival Effects On Acute Monoblastic Leukemia Cells Blood. 120: 4315-4315. DOI: 10.1182/Blood.V120.21.4315.4315 |
0.373 |
|
| 2012 |
Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, et al. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Blood. 120: 43-43. DOI: 10.1182/Blood.V120.21.43.43 |
0.339 |
|
| 2012 |
Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Kadia TM, Ravandi F, Andreeff M, Cortes JE, Hoberman K, Szarek M, Rowinsky E, et al. SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML Blood. 120: 3625-3625. DOI: 10.1182/Blood.V120.21.3625.3625 |
0.41 |
|
| 2012 |
Benito JM, Lu H, Wilson WR, Melink TJ, Bretz J, Konoplev S, Estey EH, Kantarjian HM, Gutheil JC, Andreeff M, Konopleva M. Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia Blood. 120: 3615-3615. DOI: 10.1182/Blood.V120.21.3615.3615 |
0.404 |
|
| 2012 |
Benton CB, Konopleva M, Saliba RM, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat UR, Anderlini P, Nieto Y, Parmar S, Zeng Z, Chen JJ, Rondon G, McMullin B, ... ... Andreeff M, et al. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse Blood. 120: 360-360. DOI: 10.1182/Blood.V120.21.360.360 |
0.424 |
|
| 2012 |
Gao C, Zhang W, Jacamo R, Ramachandran A, Small D, Konopleva M, Cortes JE, Andreeff M. Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations Blood. 120: 3591-3591. DOI: 10.1182/Blood.V120.21.3591.3591 |
0.374 |
|
| 2012 |
Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, ... Andreeff M, et al. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen Blood. 120: 3572-3572. DOI: 10.1182/Blood.V120.21.3572.3572 |
0.343 |
|
| 2012 |
Arana Yi CY, Kantarjian HM, Garcia-Manero G, Wierda WG, Borthakur G, Quintas-Cardama A, Konopleva M, Faderl S, Pierce SA, Andreeff M, Ravandi F, Cortes JE. Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies Blood. 120: 3557-3557. DOI: 10.1182/Blood.V120.21.3557.3557 |
0.369 |
|
| 2012 |
Tabe Y, Jin L, Hatanaka Y, Miida T, Kornblau SM, Andreeff M, Konopleva M. TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion Blood. 120: 3543-3543. DOI: 10.1182/Blood.V120.21.3543.3543 |
0.322 |
|
| 2012 |
Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Battula VL, Schober WD, Davis RE, Konopleva M, Andreeff M. NF-κB Activation in Mesenchymal Stromal Cells Mediates Leukemia Cell Chemoresistance Blood. 120: 3518-3518. DOI: 10.1182/Blood.V120.21.3518.3518 |
0.446 |
|
| 2012 |
Ruvolo PP, Jacamo R, Ruvolo VR, Burks JK, Battula VL, McQueen T, Konopleva M, Kornblau SM, Garzon R, Croce CM, Andreeff M. Exosomes Mediate Communication Between the Microenvironment and Leukemic Cells in Acute Myeloid Leukemia Blood. 120: 3469-3469. DOI: 10.1182/Blood.V120.21.3469.3469 |
0.388 |
|
| 2012 |
Ling X, Chen Y, Ruvolo PP, Ruvolo V, Wang Z, Zhang M, Shi Y, Konopleva M, Davis RE, Andreeff M. Unique Effects of p53−/− Leukemic Cells On Mesenchymal Stromal Cell Gene Expression Profile in Vitro Blood. 120: 3468-3468. DOI: 10.1182/Blood.V120.21.3468.3468 |
0.404 |
|
| 2012 |
Reinisch A, Etchart N, Hofmann NA, Frühwirth M, Ortner A, Thaler D, Feilhauer B, Hartwig UF, Beham-Schmid C, Trajanosky S, Wagner W, Alves F, Schallmoser K, Andreeff M, Strunk D. Organotypic Epigenetic Signature Predicts Bone and Marrow Niche Forming Capacity of Stromal Progenitors in a Novel Mouse Model in Vivo. Blood. 120: 2987-2987. DOI: 10.1182/Blood.V120.21.2987.2987 |
0.336 |
|
| 2012 |
Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo V, Mak DH, McQueen T, Konopleva M, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in Vitro and in Vivo by Regulating Leukemia-Stroma Interactions. Blood. 120: 2626-2626. DOI: 10.1182/Blood.V120.21.2626.2626 |
0.42 |
|
| 2012 |
Jin L, Konopleva M, Shikami M, Ikegami T, Kojima K, Andreeff M, Miida T, Tabe Y. Molecular Mechanisms of Pro-Survival and Differentiating Function of Bone Marrow-Derived Adipocytes On Acute Monoblastic Leukemia Cells. Blood. 120: 2582-2582. DOI: 10.1182/BLOOD.V120.21.2582.2582 |
0.352 |
|
| 2012 |
Wang R, Qiu YH, Yoo SY, McQueen T, Chen Y, Zeng Z, Coombes KR, Schober WD, Konopleva M, Kornblau SM, Andreeff M. Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC. Blood. 120: 2355-2355. DOI: 10.1182/Blood.V120.21.2355.2355 |
0.425 |
|
| 2012 |
Ruvolo PP, Jacamo R, McQueen T, Pan R, Samudio I, Konopleva M, Kornblau SM, Garzon R, Croce CM, Andreeff M. Suppression of Mir-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived From Acute Myeloid Leukemia Patients. Blood. 120: 2354-2354. DOI: 10.1182/Blood.V120.21.2354.2354 |
0.365 |
|
| 2012 |
Benito JM, Andrei VY, Chen Y, Hongbo L, Shi Y, McQueen T, Zweidler-McKay PA, Handisides DR, Hart C, Andreeff M, Konopleva M. Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302 Blood. 120: 1523-1523. DOI: 10.1182/Blood.V120.21.1523.1523 |
0.445 |
|
| 2012 |
Ravandi F, Alattar ML, Levis MJ, Garcia-Manero G, Richie MA, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger JA, Kadia TM, Grunwald MR, Dellasala SE, Cortes JE, Kantarjian HM. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation Blood. 120: 1519-1519. DOI: 10.1182/Blood.V120.21.1519.1519 |
0.377 |
|
| 2012 |
Yi CYA, Cortes J, Faderl S, Garcia-Manero G, Konopleva M, Estrov Z, O'Brien S, Borthakur G, Levis MJ, Thomas DA, Pierce SA, Brandt M, Pratz KW, Luthra R, Andreeff M, et al. Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia Blood. 120: 1516-1516. DOI: 10.1182/Blood.V120.21.1516.1516 |
0.381 |
|
| 2012 |
Andreeff M, Zeng Z, Kelly MA, Wang R, McQueen T, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients Blood. 120: 142-142. DOI: 10.1182/Blood.V120.21.142.142 |
0.423 |
|
| 2012 |
Benton CB, Qiu P, Ravandi F, Kantarjian HM, Garcia-Manero G, Pierce SA, Borthakur A, Konopleva M, Cortes JE, Andreeff M, Quintás-Cardama A. Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy Blood. 120: 1417-1417. DOI: 10.1182/Blood.V120.21.1417.1417 |
0.337 |
|
| 2012 |
Benito JM, Lu H, Shi Y, Jacamo RO, McQueen TJ, Konoplev S, Bueso-Ramos C, Zweidler-McKay P, Handisides D, Hart CP, Andreeff M, Konopleva M. Abstract 4641: Hypoxia activated pro-drug TH-302 induces hypoxia-dependent anti-leukemia activityin vitroandin vivo Cancer Research. 72: 4641-4641. DOI: 10.1158/1538-7445.Am2012-4641 |
0.417 |
|
| 2012 |
Jacamo RO, Chen Y, Wang Z, Ma W, Zhang M, Venkata BL, Schober WD, Davis RE, Konopleva M, Andreeff M. Abstract 4264: NFκB activation in mesenchymal stromal cells induced by leukemia-stroma interaction plays a central role in stroma-mediated chemo-resistance of leukemic cells Cancer Research. 72: 4264-4264. DOI: 10.1158/1538-7445.Am2012-4264 |
0.441 |
|
| 2012 |
Borthakur G, Duvvuri S, Tsao T, Zhang W, Ruvolo V, Lu H, Kojima K, Konopleva M, Andreeff M. Abstract 3871: Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent Cancer Research. 72: 3871-3871. DOI: 10.1158/1538-7445.Am2012-3871 |
0.458 |
|
| 2012 |
Ruvolo PP, Zeng Z, Ruvolo VR, Borthakur G, Kornblau SM, Andreeff M, Konopleva M. Abstract 3659: The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells Cancer Research. 72: 3659-3659. DOI: 10.1158/1538-7445.Am2012-3659 |
0.475 |
|
| 2012 |
Kojima K, Antony A, Vassilev LT, Andreeff M. Abstract 3021: FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1-mediated CDC25A overexpression despite the presence of intrinsic DNA damage Cancer Research. 72: 3021-3021. DOI: 10.1158/1538-7445.Am2012-3021 |
0.425 |
|
| 2012 |
Andreeff M, Chen Y, Battula VL, Hofmann NA, Reinisch A, Shi YX, Wang RY, Konoplev S, Strunk D, Konopleva M. Abstract 2971: Human extramedullary bone and bone marrow in mice: Firstin vivomodel of a genetically controlled hematopoietic environment - Role of CTGF and HIF1-α Cancer Research. 72: 2971-2971. DOI: 10.1158/1538-7445.Am2012-2971 |
0.376 |
|
| 2012 |
Pan R, Ruvolo PP, Pellecchia M, Wei J, Shi Y, Konopleva M, Reed JC, Andreeff M. Abstract 2008: Broad spectrum BH3 mimetic BI-97D6 induces apoptosis of acute myeloid leukemia cells even when co-cultured with supporting stromal cells Cancer Research. 72: 2008-2008. DOI: 10.1158/1538-7445.Am2012-2008 |
0.429 |
|
| 2011 |
Beryozkina A, Nichols GL, Reckner M, Vassilev LT, Rueger R, Jukofsky L, Middleton S, Andreeff M, Padmanabhan S, Strair R, Delioukina ML, Maslak PG, Hillmen P, Kurzrock R, Gore L, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3039. PMID 28022662 DOI: 10.1200/Jco.2011.29.15_Suppl.3039 |
0.377 |
|
| 2011 |
Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia. 26: 788-94. PMID 22033489 DOI: 10.1038/Leu.2011.285 |
0.447 |
|
| 2011 |
Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene. 31: 2849-61. PMID 21986948 DOI: 10.1038/Onc.2011.462 |
0.42 |
|
| 2011 |
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 26: 443-50. PMID 21904380 DOI: 10.1038/Leu.2011.246 |
0.466 |
|
| 2011 |
Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. Blood. 118: 4431-9. PMID 21868571 DOI: 10.1182/Blood-2011-02-334136 |
0.457 |
|
| 2011 |
Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, ... ... Andreeff M, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. Plos One. 6: e23108. PMID 21853076 DOI: 10.1371/Journal.Pone.0023108 |
0.461 |
|
| 2011 |
Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1874-7. PMID 21767516 DOI: 10.1016/J.Bbmt.2011.07.011 |
0.394 |
|
| 2011 |
Abel EL, Bubel JD, Simper MS, Powell L, McClellan SA, Andreeff M, MacLeod MC, DiGiovanni J. Protection against 2-chloroethyl ethyl sulfide (CEES) - induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway Toxicology and Applied Pharmacology. 255: 176-183. PMID 21723306 DOI: 10.1016/J.Taap.2011.06.012 |
0.303 |
|
| 2011 |
Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 25: 1711-7. PMID 21660042 DOI: 10.1038/Leu.2011.146 |
0.387 |
|
| 2011 |
Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer. 117: 4689-95. PMID 21456010 DOI: 10.1002/Cncr.26113 |
0.346 |
|
| 2011 |
Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M. Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. Journal of Cellular Biochemistry. 112: 1696-707. PMID 21360576 DOI: 10.1002/Jcb.23090 |
0.426 |
|
| 2011 |
Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (Dayton, Ohio). 29: 11-9. PMID 21280155 DOI: 10.1002/Stem.559 |
0.319 |
|
| 2011 |
Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 117: 780-7. PMID 21041716 DOI: 10.1182/Blood-2010-04-280503 |
0.421 |
|
| 2011 |
Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 96: 62-8. PMID 20952518 DOI: 10.3324/Haematol.2010.030452 |
0.335 |
|
| 2011 |
Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis : An International Journal On Programmed Cell Death. 16: 67-74. PMID 20938744 DOI: 10.1007/S10495-010-0545-1 |
0.412 |
|
| 2011 |
Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Seminars in Hematology. 47: 362-70. PMID 20875553 DOI: 10.1053/J.Seminhematol.2010.06.006 |
0.418 |
|
| 2011 |
Tabe Y, Shi Y, Zeng Z, Jin L, Zhou Y, Miida T, Andreeff M, Konopleva M. TGF-β Neutralizing Antibody 1D11 Inhibits LIF-JAK-Stat3 Signaling and Enhances Cytarabine Induced Apoptosis in AML Cells in Bone Marrow Microenvironment Blood. 118: 926-926. DOI: 10.1182/Blood.V118.21.926.926 |
0.347 |
|
| 2011 |
Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, ... ... Andreeff M, et al. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study Blood. 118: 892-892. DOI: 10.1182/Blood.V118.21.892.892 |
0.367 |
|
| 2011 |
Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Fruewirth M, Diwoky C, Rohban R, Beham-Schmid C, Andreeff M, Strunk D. Neo-Vasculogenesis In Vivo Is Facilitated by Oxygen Sensing Mesenchymal Stem and Pogenitor Cells Blood. 118: 699-699. DOI: 10.1182/Blood.V118.21.699.699 |
0.343 |
|
| 2011 |
Carter BZ, Mak DH, Qiu Y, Kornblau SM, Mak PY, Weng D, McKinlay MA, Andreeff M. Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy Blood. 118: 66-66. DOI: 10.1182/Blood.V118.21.66.66 |
0.446 |
|
| 2011 |
Gleixner KV, Herrmann H, Blatt K, Pickl WF, Konopleva M, Bharate GY, Andreeff M, Maeda H, Valent P. The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML Blood. 118: 4414-4414. DOI: 10.1182/Blood.V118.21.4414.4414 |
0.397 |
|
| 2011 |
Ruvolo PP, Ruvolo V, Zeng Z, Qui Y, Zhou L, Gallagher KE, Konopleva M, Kornblau SM, Andreeff M. The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells Blood. 118: 396-396. DOI: 10.1182/Blood.V118.21.396.396 |
0.397 |
|
| 2011 |
Takahashi K, Kantarjian HM, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes JE. FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations, Blood. 118: 3623-3623. DOI: 10.1182/Blood.V118.21.3623.3623 |
0.35 |
|
| 2011 |
Zhang W, Konopleva M, Jacamo RO, Borthakur G, Chen W, Cortes JE, Ravandi F, Andreeff M. Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML, Blood. 118: 3505-3505. DOI: 10.1182/Blood.V118.21.3505.3505 |
0.341 |
|
| 2011 |
Lu H, Battula VL, Shi Y, Lock RB, Spong S, Andreeff M, Konopleva M. Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia Blood. 118: 2593-2593. DOI: 10.1182/Blood.V118.21.2593.2593 |
0.384 |
|
| 2011 |
Borthakur G, Andreeff M, Coombes KR, Qiu YH, Duvvuri S, Zhang N, Ruvolo V, Konopleva M, Garcia-Manero G, Ruvolo PP, Cortes JE, Kantarjian HM, Kornblau SM. High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia–Time to Target Autophagy to Improve Therapy Outcomes? Blood. 118: 2513-2513. DOI: 10.1182/Blood.V118.21.2513.2513 |
0.42 |
|
| 2011 |
Jin L, Tabe Y, Kojima K, Ruvolo V, Miida T, Andreeff M, Konopleva M, Kimura S. The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia Blood. 118: 2480-2480. DOI: 10.1182/Blood.V118.21.2480.2480 |
0.454 |
|
| 2011 |
Sugihara E, Shimizu T, Kojima K, Ishizawa J, Andreeff M, Saya H. Arf and Ink4a Are Critical Factors Determining the Cell of Origin and Therapeutic Sensitivity in Myc-Induced Mouse Lymphoid Tumor Blood. 118: 2448-2448. DOI: 10.1182/Blood.V118.21.2448.2448 |
0.445 |
|
| 2011 |
Battula VL, Chen Y, Konopleva M, Andreeff M. Connective Tissue Growth Factor (CTGF) Regulates Mesenchymal Stromal Cell De-Differentiation Into Adipocyte Progenitors and Facilitates Leukemic Cell Homing to Extra-Medullary Bone Marrow Blood. 118: 2391-2391. DOI: 10.1182/Blood.V118.21.2391.2391 |
0.404 |
|
| 2011 |
Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M, Kornblau SM. Survivin Is Highly Expressed in AML Stem Cells and Predicts Poor Clinical Outcome Blood. 118: 238-238. DOI: 10.1182/Blood.V118.21.238.238 |
0.474 |
|
| 2011 |
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML Blood. 118: 1547-1547. DOI: 10.1182/Blood.V118.21.1547.1547 |
0.486 |
|
| 2011 |
Andreeff M, Kojima K, Ruvolo V, Younes A, Wei W, Konopleva M, Duvvuri S, Huang X, Wu L, Jukofsky L, Vassilev L, Zhi J, Geho D, Nichols G. Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia Blood. 118: 1545-1545. DOI: 10.1182/Blood.V118.21.1545.1545 |
0.401 |
|
| 2011 |
Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, ... ... Andreeff M, et al. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen Blood. 118: 1524-1524. DOI: 10.1182/Blood.V118.21.1524.1524 |
0.332 |
|
| 2011 |
Jin L, Tabe Y, Konopleva M, Andreeff M, Ohsaka A, Miida T. Bone Marrow-Derived Adipocytes Promote Differentiation, Proliferation and Survival of Acute Monoblastic Leukemia Cells Blood. 118: 1501-1501. DOI: 10.1182/Blood.V118.21.1501.1501 |
0.385 |
|
| 2011 |
Alvarado Y, Kantarjian HM, Ravandi F, Luthra R, Borthakur G, Garcia Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes JE. FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations Blood. 118: 1493-1493. DOI: 10.1182/Blood.V118.21.1493.1493 |
0.341 |
|
| 2011 |
Tabe Y, Jin L, Miida T, Andreeff M, Konopleva M. Growth-Inhibitory Effects of a Class I PI3K Inhibitor GDC-0941 Are Modulated by Hypoxia-Induced mTOR Pathway Activation in Mantle Cell Lymphoma Blood. 118: 1424-1424. DOI: 10.1182/Blood.V118.21.1424.1424 |
0.455 |
|
| 2011 |
Chen Y, Jacamo RO, Hofmann NA, Shi Y, Wang R, Konoplev S, Strunk D, Konopleva M, Andreeff M. Human Extramedullary Bone and Bone Marrow in Mice: First In Vivo Model of a Genetically Controlled Hematopoietic Environment Blood. 118: 1323-1323. DOI: 10.1182/Blood.V118.21.1323.1323 |
0.429 |
|
| 2011 |
Kojima K, McQueen T, Shpall E, Wang R, Andreeff M. 506 p53 Activation of Mesenchymal Stromal Cells (MSC) Partially Abrogates Microenvironment-Mediated Resistance to FLT3 Inhibition in FLT3/ITD AML Clinical Lymphoma Myeloma and Leukemia. 11: S127. DOI: 10.1182/Blood.V116.21.2151.2151 |
0.443 |
|
| 2011 |
Abel EL, McIvor E, Bubel JD, Simper MS, Powell L, Fields TY, Andreeff M, MacLeod MC, DiGiovanni J. Abstract 1339: Upregulation of the glutathione detoxification pathway protects against cytotoxicity induced by the alkylating agent, 2-chloroethyl ethyl sulfide (CEES) Cancer Research. 71: 1339-1339. DOI: 10.1158/1538-7445.Am2011-1339 |
0.347 |
|
| 2011 |
Wang R, Shi Y, Zeng Z, Schober W, Tarrand J, McQueen T, Hopwood V, Konoplev S, Korchin B, Fang B, Konopleva M, Andreeff M. 903 Bone Marrow Derived Human Mesenchymal Stem Cells have the Capacity to Differentiate into B-Cells in Vivo Clinical Lymphoma Myeloma and Leukemia. 11: S135. DOI: 10.1016/J.Clml.2011.05.034 |
0.361 |
|
| 2011 |
Andreeff M, Battula VL, Wang R, Chen Y, Ling X, Jacamo R, Spaeth E, Konoplev S, Burks J, Hazen A, Schober W, Lu H, Mak D, McQueen T, Shi Y, et al. 900 Multipotent Mesenchymal Stromal Cells (MSC) - Evolving Role in Cancer and Leukemia Therapy Clinical Lymphoma Myeloma and Leukemia. 11: S134-S135. DOI: 10.1016/J.Clml.2011.05.033 |
0.359 |
|
| 2011 |
Carter B, Mak D, Schober W, Konopleva M, Cortes J, Kantarjian H, Koller E, Huang Z, Reed JC, Andreeff M. 802 Overcoming Imatinib Resistance by Targeting XIAP and ARC (Apoptosis Repressor with Caspase Recruitment Domain) in Blast Crisis CML Cells Clinical Lymphoma Myeloma and Leukemia. 11: S133. DOI: 10.1016/J.Clml.2011.05.031 |
0.335 |
|
| 2011 |
Frolova O, Frankel A, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. 801 IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells in CML Clinical Lymphoma Myeloma and Leukemia. 11: S132-S133. DOI: 10.1016/J.Clml.2011.05.030 |
0.372 |
|
| 2011 |
Mak D, Manton C, Andreeff M, Carter B. 503 Antagonizing Inhibitors of Apoptosis (IAP) Family of Proteins Sensitizes AML to Chemotherapy-Induced Apoptosis Clinical Lymphoma Myeloma and Leukemia. 11: S125-S126. DOI: 10.1016/J.Clml.2011.05.016 |
0.311 |
|
| Show low-probability matches. |